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ABSTRACT 
Hydrocephalus is a disease characterized by an increase in cerebrospinal fluid (CSF) in the 
ventricles of the brain. This manifests as a result of either overproduction or underabsorption of 
CSF leading to increases in pressure, swelling and loss of brain matter. Current treatments for this 
disease include surgical interventions via the introduction of shunts or endoscopic third 
ventriculostomy, both of which aim to redirect flow of CSF in to another cavity for absorption. 
Limited pharmacotherapies are available in the treatment of hydrocephalus, and there exists a 
clinical need for drug therapies, which can ameliorate the pathophysiology associated with 
hydrocephalus and ventriculomegaly. CSF is produced primarily by the choroid plexus (CP), 
found in the ventricles of the brain. Composed of a high resistance epithelium surrounding a 
capillary network, the CP epithelium acts as a barrier, regulating ion transport between the CSF 
and blood. Transient Receptor Potential Vanilloid-4 (TRPV4) is a nonselective Ca2+-permeable 
cation channel expressed in the CP which is being investigated for its role in CSF production.  
 
To study hydrocephalus, we utilize two model systems; the TMEM67-/- Wpk rat, and the PCP-R 
cell line. The Wpk rat model is used to study the effects of drug intervention on the development 
and progression of hydrocephalus. The PCP-R cell line is utilized for studies which aim to 
understand the mechanisms by which CSF is produced. Using Ussing chamber electrophysiology, 
we are able to study the role of specific channels, transporters and modulators in driving epithelial 
ion flux across the CP.  
 
This research aims to establish a role for TRPV4 in production and regulation of CSF, and to 
interrogate a mechanism by which this ion transport occurs. The chapters that follow describe 
components of the pathway by which TRPV4 is activated and ion flux is stimulated. 
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 INTRODUCTION 
1.1 Hydrocephalus 
Hydrocephalus, colloquially known as “water on the brain” is a condition in which the 
cerebrospinal fluid (CSF) production, secretion, absorption and/or composition may be aberrant, 
and can manifest in one of several ways culminating with the enlargement of the cerebral ventricles. 
Communicating hydrocephalus is a state in which CSF is either overproduced, or underabsorbed 
(10,13,45). Alternatively, hydrocephalus can develop as a result of a blockage in the CSF 
circulatory pathways called non-communicating hydrocephalus. Non-communicating 
hydrocephalus typically occurs as a result of aqueductal stenosis, the blocking of the cerebral 
aqueducts (11,31). Various tumors including cerebral tumors, intraventricular tumors of the 
ependyma, or choroid plexus papilloma have all been shown to result in hydrocephalus. 
Additionally, genetic defects, intracranial hemorrhaging, inflammation due to chronic or acute 
infection, and head trauma can also lead to the development of hydrocephalus (31,53).  
 
Hydrocephalus may occur at any age in individuals, with multiple unique etiologies contributing 
to the disease. In newborns, this causes the characteristic doming of the cranium when left 
untreated (10,45,84). In the elderly population, neurodegenerative disease has recently also been 
implicated in occurrences of hydrocephalus (11,84).  In contrast to classical hydrocephalus, which 
is marked by increased pressure on the brain due to the accumulation of CSF in the ventricles, the 
disease may also manifest in the elderly population as normal pressure hydrocephalus (NPH) (84). 
Though not well understood, this form of hydrocephalus generally does not feature increased 
intracranial pressure, while still typically displaying enlarged cerebral ventricles. Recent literature, 
however, suggests that NPH may also display aberrant intracranial pressures. Rarely diagnosed, 
due to similarities with other neurodegenerative diseases, NPH is considered one of the more 
readily treated and reversible forms of hydrocephalus if identified early in its progression (84). 
 
Hydrocephalus in the juvenile population occurs at a rate of approximately 1 in 1000 live births 
and is among the most severe forms of the disease (85,97). The most common cause of 
hydrocephalus in infants is a result of intraventricular hemorrhaging, resulting in the development 
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of post-hemorrhagic hydrocephalus of prematurity (PHHP) (28). In addition, genetic defects, spina 
bifida, and traumatic brain injury are among other causes that also lead to the accumulation of CSF 
in the ventricles, causing significant increases in intracranial hydrostatic pressure and resulting in 
loss of brain matter, neuronal cell death, cranial doming, and potentially death (85). 
 
1.2 Treatment of Hydrocephalus 
Surgical intervention is the most common treatment for hydrocephalus. Most common is shunt 
implantation, which redirects flow of CSF drainage in to an alternative body cavity. Additionally, 
endoscopic third ventriculostomy (ETV) is utilized in non-communicating hydrocephalus. By 
creating a small perforation in the third ventricle via an endoscope, the blockage can be bypassed 
allowing CSF to be redirected to an alternative cavity for reabsorption (54,97). Also in clinical 
trials is choroid plexus cauterization, which involves irreversible destruction of the main source of 
CSF production within the ventricles (54). Surgical interventions come with significant risk; shunt 
implantation, currently the most widely used treatment for hydrocephalus, often requires surgical 
revision to treat infections, blockages or juveniles outgrowing their shunts. The rate of revision is 
approximately 70% at one year post-implantation of the shunts in the pediatric population, with 
lower rates in the adult population (97).  
 
ETVs and choroid plexus cauterization also come with considerable risk. In the case of ETVs, 
closure of the hole can occur, resulting in ETV failure and necessitating the implantation of a shunt 
to redirect CSF flow (54,97). Finally, choroid plexus cauterization is an irreversible procedure 
which results in destruction of the CSF-producing choroid plexus. This procedure also comes with 
a failure rate of 59% at 12 months (54,97). Failure is defined as either recurrence of symptomatic 
hydrocephalus, CSF infection, or significant intraoperative complication, including neurological 
defects and death. Furthermore, if successful, the long-term effects of this procedure on developing 
children is currently unknown. While more often performed in underdeveloped nations where 
access to surgical care for shunt revisions is less accessible, cauterization nevertheless is a 
relatively new procedure being established across the globe.  
 
 
 
16 
The risks and side effects of any of the surgical interventions highlight the need for non-invasive 
pharmacological alternatives to treat hydrocephalus.  The studies in our laboratory are directed 
toward a better understanding of the process involved in CSF production and, consequently, an 
identification of potential drug targets. 
 
1.3 The Choroid Plexus 
The human brain weights approximately 1500 grams, yet while cushioned in the CSF, which 
provides neutral buoyancy, the net weight of the brain is only observed to be about 25 to 50 grams 
(11,14). CSF protects the brain from injury, by reducing the effective weight of the tissue (11,14). 
At any given time, the body only contains 150 ml of CSF, however the body produces roughly 500 
ml of CSF daily, almost a 3-time turnover rate (11,15,53,101). The bulk of this CSF is produced 
by the choroid plexus (CP), a highly vascularized branching network of cells extending outward 
in to the cerebral ventricles (14,15,19,20,38,53,56,62,74,90,101). The choroid plexus is composed 
of a high-resistance monolayer epithelium surrounding a fenestrated capillary bed and is present 
in both lateral ventricles, as well as the third and fourth ventricles (14,15,19,20,53,56,62,74,90). 
Approximately 70-80% of the CSF is produced by the choroid plexus epithelium, with the 
remainder produced by the ependymal cells lining the ventricles, as well as cells lining the 
subarachnoid space (11,15,74). CSF is believed to play an integral role in the removal and 
clearance of waste products from the central nervous system (CNS) (16,27,38,80,103). This 
appears to be controlled primarily by the wake-sleep cycle, allowing for daily recycling of CSF, 
reducing the buildup of potentially toxic chemicals within the CNS (27). 
 
CSF is produced by the flow of water and solutes from blood, via the choroid plexus epithelial 
cells, to the intraventricular space (11,15,18,69,71,74,90). Small ions, such as sodium, potassium, 
chloride and bicarbonate are transported across the epithelium via transport proteins and ion 
channels, representing both active and passive transport events. The presence of tight junctions 
restricts most solute movement and limit paracellular ion transport (39,56,75,77,92). Water moves 
via aquaporins in a transcellular fashion, as well as via paracellular tight junctional complexes 
(18,69,74). Differences in the composition of blood and CSF highlight the complex role of the 
choroid plexus in regulating and producing CSF (75,90). The CSF is hyperosmolar with regard to 
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blood, chloride increased in the CSF, while calcium and potassium are observed to be slightly 
higher in the plasma (75). Therefore, ion transporters located on the apical or basolateral 
membranes of the choroid plexus are potential targets for pharmacological regulation of ion flux 
and CSF production in hydrocephalic cases. 
 
1.4 Transient Receptor Potential Vanilloid 4 
Water movement and CSF production are driven by the transepithelial flow of ions from the blood 
to the CSF, which are transported via ion channels and transporters (67,76,86). One particular 
channel of interest is Transient Receptor Potential Vanilloid-4 (TRPV4). TRPV4 is a non-selective, 
calcium-permeable cation channel located on the apical membrane of the choroid plexus 
(67,68,76). TRPV4 is both mechano- and osmo-sensitive, allowing it to play a key role in many 
regulatory events among various cells, including Ca2+ homeostasis and regulatory volume decrease 
(RVD) (6,9,22,67,100). 
 
TRPV4 can be activated by osmotic stress, pressure, changes in fluid flow, sheer shress, as well 
as chemical activators such as 4α-PDD, arachidonic acid metabolites, and synthetic compounds 
such as GSK1016790A (76,99,100). When activated, TRPV4 allows for movement of ions, 
including calcium, potassium and sodium, across the membrane of the cell (6,22,55,67,77,95).  
Influx of these ions into the cell results in stimulation of secondary proteins, notably calcium-
activated potassium and calcium-activated chloride channels (6,55,57,58,76). When stimulated, 
these channels allow for additional movement of ions across the cell membranes. This 
transepithelial flow of ions may result in the movement of water and may ultimately contribute to 
the production of CSF.  
 
In overventilated mice, TRPV4 inhibition prevented vascular leakage and lung inflammation (65). 
Additionally, following traumatic brain injury, TRPV4 expression was increased in rat 
hippocampus, dependent on the NKCC1 cotransporter (61). In mouse mammary cells, TRPV4 
activation was shown to increase intracellular calcium, resulting in acute increases in transcellular 
conductance (77). This increase in conductance occurred in tandem with activation of the BK 
channel, a calcium activated cation channel. These pathways have multiple physiological effects, 
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suggesting TRPV4 TRPV4 therefore may act as a hub protein, integrating complex molecular 
signals to regulate ion flux across cells (22,76). 
1.5 The WPK Rat Model of Hydrocephalus 
To study the channels and pathways mentioned, we utilize an in vitro choroid plexus cell line 
model, as well as an in vivo Wpk rodent model. The WPK rat model is orthologous to Meckel-
Gruber Type 3 syndrome (MKS3), a ciliopathy resulting in polycystic kidney disease as well as 
hydrocephalus (81,88). The WPK rat contains a single C to T point mutation in the TMEM67 gene 
on chromosome 5, resulting in a homozygous recessive phenotype which displays both severe 
polycystic kidney disease as well as a rapidly progressing hydrocephalus. The homozygous 
animals do not survive to weaning, providing a severe model analogous to neonatal hydrocephalus 
(81). The heterozygous mutants display a mild, asymmetrical hydrocephalus phenotype which is 
noticeably less severe than the homozygous mutants. This hydrocephalus progresses more slowly 
with the animals not exhibiting signs of distress until about one year of age (81). Interestingly, 
unlike the homozygous animals, the heterozygous population do not develop polycystic kidney 
disease. The heterozygous animals therefore appear to more closely mimic slowly progressing 
hydrocephalus typical of the geriatric population.   
 
Preliminary animal studies with the Wpk rats have shown that inhibition of TRPV4 in the 
TMEM67-/- WPK rat model of hydrocephalus results in a reduction in ventricular volume (21,88). 
When treated with the TRPV4 inhibitor RN1734, the ventricular volumes of juvenile homozygous 
animals were shown to be similar to those of wild type animals treated with either RN1734 or 
vehicle, and significantly smaller than the ventricular volumes of vehicle treated homozygous 
animals (Figure 1.1). This difference in ventricular volume is defined as the change in ventricular 
volume from day 7 to day 15. These data suggest that TRPV4 may be an intriguing drug target to 
restrict production of CSF and ameliorate the pathophysiology associated with hydrocephalus. 
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1.6 Porcine Choroid Plexus Cell Line 
The porcine choroid plexus-Riems (PCP-R) cell line was first described in 2012 by Schroten et al. 
(79). This in vitro model develops a high resistance monolayer, and expresses all proteins 
examined thus far which are seen in native CP tissue, with the exception of NCBE. The PCP-R 
cells grow as a polarized epithelium, allowing for the expression of transporters to specific 
membranes, which in the native tissue allows the CP to regulate ion flux across the epithelium and 
produce CSF (56,79). In our laboratory, we utilize the PCP-R cells for electrophysiological 
experiments as well as for studies utilizing immunofluorescence (IF), reverse-transcriptase based 
PCRs (RT-PCR), and quantitative PCR (qPCR). PCP-R cells are grown on permeable supports 
until confluent, ~10-11 days. Cells are then mounted in Ussing chambers, which are used to model 
the in vivo cell environments (76,86). These cells allow for studies related to the nature of 
transepithelial ion flux in the choroid plexus, through varied use of specific inhibitors, intracellular 
mediators such as cAMP, as well as modulation of the extracellular environment including 
temperature, fluid pressure, or ion gradients across the membrane (76,86). Short circuit current, a 
measure of net ion movement, and conductance, a measure of barrier permeability are recorded. 
 
To elucidate a mechanism for TRPV4-mediated ion flux, we use inhibitors of various transporters, 
ion channels, kinases and other genes and observe their effects on transepithelial ion flux and 
conductance following activation of TRPV4 with its specific agonist GSK1016790A. These 
studies allow us to determine the role specific proteins play in the TRPV4 pathway, giving insight 
to the mechanism and providing new pharmacological targets for modulating TRPV4 activity.  
 
1.7 Chloride Transporters 
In the CP, [Cl-] is exquisitely regulated via apically and basolaterally bound transporters and ion 
channels (14,15,19,20). The movement of Cl- may be key to producing CSF; Cl- must be actively 
transported against its ionic gradient via transcellular transport (14,19). Cl- is thought to be 
transported down its osmotic gradient into the cell via the basolaterally localized Cl-/HCO3- 
exchanger AE2 (Anion exchange protein 2, SLC4A2), resulting in net influx of Cl- and efflux of 
HCO3- into the plasma (14,15,19). This influx of Cl- appears to be driven by activity of the enzyme 
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carbonic anhydrase (19,20,74). Carbonic anhydrase is an enzyme found within the CP which 
converts intracellular CO2 and water into HCO3- and free H+. This conversion of CO2 may in part 
be responsible for the influx of Cl- necessary to drive fluid movement in a transcellular fashion 
(19). The resulting increase in intracellular [Cl-] in turn drives the extrusion of Cl- via apically 
localized transporters (14,15). In addition to AE2, NCBE (NBCn2, SLC4A10) is also responsible 
for Cl-/HCO3- exchange, working in the opposite direction to AE2 (19,20). NCBE activity results 
in net influx of Na+ and HCO3- from serum to the cytoplasm, coupled with Cl- efflux in to the 
serum (19,20). 
 
Calcium-activated chloride channels (CaCC’s) are a group of proteins that are activated by 
increases in intracellular [Ca2+] and respond by secreting Cl- (66,72,93). This family of proteins is 
comprised primarily of the anoctamin family (17,66,72,93). The anoctamins consist of the 
TMEM16 genes, of which TMEM16A (ANO1) is a member. Originally identified in 2008, 
TMEM16A is an apically localized Cl- channel, which, in intestinal and airway epithelia contribute 
to Cl- conductances in a minor role (66). In isolated murine CP cells, TMEM16A was shown to 
contribute to Cl- efflux induced by increases in intracellular [Ca2+] (93).  
 
The cystic fibrosis transmembrane regulatory protein (CFTR) is perhaps the most well-described 
chloride channel in transporting epithelia. Of the more than 2000 gene mutations described in the 
gene, more than 200 have been shown to cause a cystic fibrosis phenotype (17). Some controversy 
exists as to the role CFTR plays in Cl- transport in the CP (44,51,52). Current consensus opinion 
is that CFTR mRNA is not present in the CP, and functional studies have demonstrated that CFTR 
does not contribute to Cl- currents in the CP epithelium (19). 
1.8 Calcium-Activated Potassium Channels 
Calcium-activated potassium channels (KCa) are a group of proteins that are activated by increases 
in intracellular calcium (61,96,98). These include the large conductance (BK, KCa1.1, KCNMA1), 
intermediate conductance (IK, KCa3.1, KCNN4), and small conductance (SK1-3, KCa 2.1, 2.2, 2.3, 
KCNN1-3) potassium channels (1,7,8,30,59,71,87,96). Ca2+-activated K+ channels are widely 
expressed in epithelia, smooth muscle and neuronal tissues (1,4,7,8,30,41,59,71,87,96,98). These 
channels function to secrete K+ in to the luminal space, contributing to polarization of membrane 
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potentials and limiting [Ca2+] influx (1,7,8,30,41,59,96,98). The BK channel has been shown to 
form a Ca2+-signaling complex with ryanodine receptors, resulting in arterial dilation and smooth 
muscle hyperpolarization (29). Additionally, apically localized BK channel can be activated by 
TRPV4 in mammary cells causing an increase in transcellular conductance (77). SK channels are 
typically expressed in the nervous system, where they contribute to hyperpolarization following 
action potentials (30,98). The IK channel is found in many epithelia, including surface skin cells, 
secretory gland epithelia, distal colon and rat choroid plexus (41,87,94). In arteriolar endothelial 
cells, the IK channel appears to contribute to hyperpolarization leading to a reduction in arterial 
tone and results in vasodilation (4). 
1.9 Sodium-Potassium-Chloride and Potassium-Chloride Cotransporters 
Recent published studies have suggested that the sodium-potassium-chloride cotransporters may 
also play a role in CSF production in the choroid plexus (25,39,42,49,50,63,102). The sodium-
potassium-2 chloride (NKCC) cotransporter exists in humans in two forms; NKCC1 and NKCC2, 
encoded by SLC12A2 and SLC12A1, respectively (3,42). NKCC1 is typically found in the brain 
parenchyma, and specifically in the apical membrane of the choroid plexus, while NKCC2 is 
localized to the basolateral membrane of the thick ascending loop of Henle in the kidney 
(3,42,47,50). NKCC1 is more ubiquitously expressed throughout transporting epithelia while 
NKCC2 is thought to be kidney-specific (3,42,50). This transmembrane protein, when activated, 
transports two molecules of chloride for every one molecule of potassium and sodium.  
 
Recently, it was suggested that alterations in osmotic concentrations can alter the direction of ion 
flux of NKCC, changing the driving forces from net influx to net efflux of ions (25,39). It has been 
suggested that this transporter may be an interesting target for CSF regulation (49). In the CP, it 
appears that NKCC may also be responsible for establishment of the electrochemical gradient, 
allowing for transepithelial ion flux and CSF secretion (8,25). Also of interest are the potassium 
chloride cotransporters (KCC1-4, SLC12A4-7) and the sodium-chloride cotransporter (NCC, 
SLC12A3). While not as well understood as the NKCCs, these proteins have been identified in the 
choroid plexus and may also contribute to fluid production (19,20,47,50,63,92,102). KCC4 is 
thought to be localized apically, while KCC3 is basolateral (15,19,20,48). Both KCCs in the CP 
appear to work in net efflux, driving Cl- and K+ efflux from the cytoplasm (15,19,20). 
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1.10 STE20/SPS1-Related Proline-Alanine-Rich Protein Kinase 
TRPV4, NKCCs, and the KCCs are regulated by various intracellular mediators. Of particular 
interest is STE20/SPS1-related proline-alanine-rich protein kinase (SPAK). Evolutionarily 
redundant for OSR1, SPAK is a kinase which is phosphorylated by WNK (with no lysine, (K)) 
kinases, and in turn phosphorylates downstream targets (24,25,33-35,49,64,70,73,78). Called the 
WNK-SPAK/OSR1 pathway, this mechanism results in phosphorylation and activation of the 
NKCCs (2,3,24-26,32-35,37,43,46,47,64,73). This regulation of NKCC by SPAK may play a vital 
role in cell volume regulation and homeostasis (3,42,78). SPAK is also known to phosphorylate 
the NCC and the KCC cotransporters. Phosphorylation of NCC by SPAK results in activation, 
similar to NKCC, while phosphorylation of the KCCs by SPAK results in inhibition of the 
cotransporters (26,46,78). Anecdotal evidence exists to suggest that the WNK-SPAK/OSR1 
pathway may also regulate TRPV4 activity. In human endothelial kidney (HEK-293) cells, WNK4 
coexpression with TRPV4 resulted in downregulation of TRPV4 (32,36). Immunoprecipitation 
however was unable to show a direct effect of WNK4 on TRPV4, and the mechanism of regulation 
is of yet unknown.  
 
1.11 Translational Potential 
Hydrocephalus affects more than 6 million individuals worldwide, yet little is known about the 
mechanisms by which the disease develops. Currently, the only widely used treatments clinically 
are the insertion of shunts, which are prone to failure, particularly in the young (48). In some parts 
of the world with limited surgical availability, experimental treatments such as endoscopic third 
ventriculostomies and choroid plexus ablation are becoming more common (48,91). It is of great 
importance therefore to develop non-surgical treatments for hydrocephalus.  
 
To develop better drug targets, more must be understood about the underlying mechanisms of CSF 
production by the choroid plexus. The focus of our research and in particular my project is to better 
understand the mechanisms responsible for production and regulation of CSF. Each of the 
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following chapters reflects different aspects of the projects to which I’ve contributed. Chapters 2 
and 5 are published data, while chapters 3 and 4 detail studies that are being prepared for 
publication. Chapters 2, 3 and 5 each have a preface which outlines my unique contributions to the 
work, while chapter 4 is ongoing work in which I have been solely involved thus far.  
 
Chapter 2 is a publication in which we characterized the PCP-R cell line, the basis for much of our 
mechanistic studies. This manuscript, titled “Activation of TRPV4 Stimulates Transepithelial Ion 
Flux in a Porcine Choroid Plexus Cell Line,” was published in American Journal of Physiology: 
Cell Physiology in December 2018. The focus of this publication was to describe the interactions 
between TRPV4 and calcium activated potassium channels, and describe the role TRPV4 plays in 
stimulating transepithelial ion flux. Chapter 3 is a manuscript which is currently being prepared 
for publication, which attempts to elucidate the role of NKCC in the TRPV4 pathway and 
investigate the role SPAK plays in regulation of this pathway. Chapter 4 contains data pertaining 
to the role of calcium activated chloride channels in the TRPV4 mechanism and addresses the 
question of chloride regulation in the choroid plexus. Chapter 5 is a paper which was published in 
August 2019. This paper outlines the role of inflammatory mediators and cytokines play in 
modulating TRPV4 activity in the PCP-R cell line. 
 
These studies contribute to establishing a mechanism of activation and regulation for TRPV4 in 
the choroid plexus. Taken together with the emerging animal data, these data demonstrate a role 
for TRPV4 in the development of hydrocephalus and offer a potential pharmacological target 
through which the production of CSF may be altered. Additionally, these studies contribute to an 
understanding of intracellular mechanisms by which various ions are regulated, leading to CSF 
production.  
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Figure 1.1 Ventricular Volumes of Treated vs Untreated WPK Rats. 
Wild-type (WT), TMEM67(+/-), and TMEM67(-/-) pups were treated with 4 mg/kg body weight 
RN1734, a TRPV4 antagonist daily via i.p. injections from day 7 to 14. MRIs were taken on day 
15. Hydrocephalus results in an increase in ventricular volume, shown from day 7 to 15 as Δ 
ventricular volume. This increase in ventricular volume was inhibited by drug treatment in 
homozygous rat pups (p = 0.03). Figure is unpublished data from the Blazer-Yost lab.  
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 ACTIVATION OF TRPV4 STIMULATES ION FLUX IN 
PCP-R CELLS 
2.1 Preface 
The journal article which immediately follows was accepted by American Journal of Physiology: 
Cell Physiology in May 2018. To this publication, I contributed electrophysiological experiments 
utilizing inhibitors of TRPV4 to determine efficacy of the inhibitors in our porcine choroid plexus 
cell line (Figures 2,4). These involved treating cultured cells with specific inhibitors of TRPV4, to 
show complete inhibition of transepithelial ion flux mediated by activation of TRPV4. 
Additionally, I conducted experiments demonstrating that use of inhibitors of several calcium-
activated potassium channels were incapable of blocking the TRPV4-mediated ion flux. This 
included use of iberiotoxin to block the BK channel, as well as Apamin, Tamapin, Lei-Dab7, and 
Scyllatoxin to block the SK channels (Figures 8-9). This series of experiments showed that changes 
in short circuit currents observed upon activation of TRPV4 were not dependent on the large, or 
small conductance potassium channels.  
 
My contributions further included design of all PCR primers utilized, as well as designing and 
performing all RT-PCR experiments. These experiments confirmed that mRNAs for the SK2 
channel, as well as the IK channel were present in the PCP-R cell line, showing the ability of cells 
to transcribe these proteins. Additionally, we showed that TRPV4 was well expressed, an expected 
result from the activation of TRPV4, and that the BK channel was not expressed in our cell line, 
contradictory to the expression patterns in other tissues. 
 
My final contributions to the paper involved drawing and designing a diagram of the choroid 
plexus epithelium (Figure 12). Additionally, I was involved in the manuscript preparation both 
prior to submission and during the review process, as well as preparing the primary figures for 
experiments I contributed towards. Additionally, I contributed to answering reviewers’ questions 
and editing the manuscript accordingly following submission of the manuscript. 
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2.3 Abstract 
The choroid plexus (CP) epithelium plays a major role in the production of cerebrospinal fluid 
(CSF).  A polarized cell line, the porcine choroid plexus – Riems (PCP-R) line, that exhibits many 
of the characteristics of the native epithelium, was used to study the effect of activation of the 
transient receptor potential vanilloid 4 (TRPV4) cation channel found in the PCP-R cells as well 
as in the native epithelium. Ussing-style electrophysiological experiments showed that activation 
of TRPV4 with a specific agonist, GSK 1016790A, resulted in an immediate increase in both 
transepithelial ion flux and conductance.  These changes were inhibited by either of two distinct 
antagonists, HC067047 or RN1734.  The change in conductance was reversible and did not involve 
disruption of epithelial junctional complexes.  Activation of TRPV4 results in Ca2+ influx, 
therefore, we examined whether the electrophysiological changes were the result of secondary 
activation of Ca2+-sensitive channels. PCP-R cells contain two Ca2+-activated K+ channels, the 
small conductance (SK) 2 and the intermediate conductance (IK) channels.  Based on inhibitor 
studies, the former is not involved in the TRPV4-mediated electrophysiological changes while one 
of the three isoforms of the IK channel (KCNN4c) may play a role in the apical secretion of K+.  
Blocking the activity of this IK isoform with TRAM34 inhibited the TRPV4-mediated change in 
net transepithelial ion flux and the increased conductance.  These studies implicate TRPV4 as a 
hub protein in the control of CSF production through stimulation by multiple effectors resulting in 
transepithelial ion and subsequent water movement.  
2.4 Introduction 
The choroid plexus (CP), formed by a tufted capillary surrounded by an epithelial monolayer, is 
thought to be responsible for the majority of cerebrospinal fluid (CSF) production.  CSF cushions 
and protects the brain, substantially reducing the effective weight of the organ.  CSF also serves 
as a medium to deliver nutrients, effectors and immune modulators as well as to remove toxins 
including β-amyloid (6, 22, 27, 36).  In addition, CSF contributes to more subtle functions that are 
dependent on minor changes in electrolyte composition such as modulating sleep/wake cycles and 
neuronal excitability (10).   
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The CP is among the most secretory of the organ systems, with approximately 2 grams of tissue 
producing in excess of 0.5 liters of CSF per day in an adult human (7, 22, 34).  The capillary bed 
that serves as the source of the major components of the CSF is lined with a fenestrated 
endothelium, therefore, producing a plasma filtrate based primarily on molecular size.  The CP 
epithelium that surrounds the capillaries forms the blood-CSF barrier and is the basis for the 
selectivity that is responsible for the unique composition of the CSF by the regulated movement 
of electrolytes and water (7, 22, 34).   Notably, in addition to a pH differential in which CSF is 
slightly more acidic (pH 7.27) compared to the interstitial fluid (pH 7.46), there are differences in 
electrolyte composition between the CSF and the plasma (22).  Transporters and regulatory 
proteins present in the CP epithelial cells are responsible for creating and maintaining these crucial 
compositional differences.  As recently reviewed (22), the major electrolyte transporters and 
aquaporins present in the CP have been elucidated, and their polarization within the epithelial 
membranes is well established. Other, less well-documented transporters remain to be identified.  
The effectors that control the expression and activation of these CP transport proteins remain 
largely unknown.  Because the composition and volume of the CSF is not static but varies on a 
diurnal basis (10), understanding the complex mechanisms controlling the production of CSF is 
crucial for understanding critical brain functions in both health and disease. 
 
Transient receptor potential vanilloid 4 (TRPV4) is one member of a family of mechano- and 
osmotic-sensitive channels found in multiple cell types, including the CP (16, 21, 33). When 
activated, TRPV4 acts as a non-specific cation channel that allows the influx of Ca2+ into cells.  In 
several tissues, TRPV4 serves as a hub protein that coordinates multiple internal and external 
signals with the activation of electrolyte and water channels in a tissue-specific manner (9).   
TRPV4 has been shown to have direct effects on transport proteins in the brain including 
aquaporin-4 in astrocytes (5), and the Ca2+-activated Cl- channel, TMEM16A, in primary cultures 
of CP cells (30). In the hippocampus, TRPV4 was elevated 8 hours after traumatic brain injury 
and the increased expression was dependent on NKCC1 (18), a co-transporter which is also found 
in the apical membrane of native CP epithelia (35).  Calcium influx through TRPV4 has also been 
shown to stimulate Ca2+-sensitive K+ channels in a tissue-specific manner. Ca2+-sensitive K+ 
channels fall into three categories:  BK (big conductance; KCa1.1); IK (intermediate conductance; 
KCa3.1; KCNN4); or SK1, SK2, SK3 (small conductance; KCa 2.1, 2.2, 2.3) channels (28). In 
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endothelial cells of smaller resistance arteries and arterioles, low intraluminal pressure stimulates 
TRPV4 causing localized Ca2+ sparkletts which activate IK channels and reduce arteriole tone (2).  
In these resistance arteries, activation of the TRPV4 did not stimulate SK channels although the 
SK channel KCa2.3 is present in the endothelial cells.  In freshly isolated cerebral myocytes, there 
are indications that TRPV4 forms a Ca2+ signaling complex with ryanodine receptors and BK 
channels that elicits smooth muscle hyper-polarization and arterial dilation (11). TRPV4 activation 
also resulted in the secondary activation of the BK channel in a high resistance mammary epithelial 
cell line (23). TRPV4 has been identified on the apical membrane of native CP epithelia (24, 30) 
and in primary CP cell lines (20, 30). 
 
The complexity of the CP in vivo makes studying the regulation of electrolyte transporters 
challenging.  Unfortunately, most in vitro primary cultures of CP epithelial cells exhibit a very low 
transepithelial electrical resistance (TER) that is inconsistent with the barrier function of these 
epithelia in vivo.  In addition, a low transepithelial resistance poses technical difficulties when 
measuring permeability changes that may be part of an effector response.   Continuous cell lines 
recently established in one of our laboratories (H.S. and C.S.) are, to our knowledge, the only lines 
described that exhibit a moderate to high TER (25, 26).  The porcine choroid plexus – Riems (PCP-
R) cell line expresses tight junction components, including claudin-1, claudin-3, ZO-1 and 
occludin, and develops a high transepithelial resistance when grown on permeable supports 
indicating the formation of a barrier epithelium (25).  In the current studies, the PCP-R line was 
used to examine the physiological effects of TRPV4 stimulation on the permeability of the 
epithelial monolayer and on activation on electrogenic transepithelial ion flux. 
2.5 Materials and Methods 
Cell Culture: The PCP-R cell line was derived from primary cultures of porcine choroid plexus 
(25).  PCP-R cells were grown in DMEM containing 4.5 g /L glucose, 3.7 g/L NaHCO3, 24 mM 
HEPES, 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 5 µg/ml insulin. 
Cells were grown in a 75 cm2 flask until confluent (typically 7-10 days). For electrophysiology 
experiments, cells were trypsinized and  seeded onto a permeable, 0.4 µm pore diameter, filter 
support (EMD Millipore, Billerica, MA) at 50% confluent density in PCP-R media  and placed 
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inside a 6-well plate (Corning, Corning, NY). The bottom of each well was bathed in 2 ml of PCP-
R media, and 1.5 ml of the media containing cells was placed on the top of the filter. PCP-R media 
was replaced thrice weekly. 
 
Electrophysiology: For electrophysiological analyses, PCP-R cells were cultured on 6-well, 
Transwell filters for 9-12 days. Ussing-style electrophysiological techniques were used to monitor 
TER/conductance as well as changes in electrogenic transepithelial ion flux. Filters were excised, 
mounted in Ussing chambers, and connected to a DVC-1000 Voltage/Current Clamp (World 
Precision Instruments) with voltage and current electrodes on either side of the membrane. Each 
half of the chamber contains a tapered fluid compartment with fittings for voltage electrodes (close 
to the epithelial membrane) and current electrodes (at the opposite end of the chamber). Each fluid 
chamber was water jacketed to maintain a constant temperature (37oC). The cells were bathed in 
serum-free media. Media were circulated in the chambers and oxygenated by means of a 5% 
CO2/O2 gas lift. The spontaneous transepithelial potential difference was measured and clamped 
to zero, and the resultant short-circuit current (SCC) was monitored continuously as a 
measurement of net transepithelial ion flux. As per convention, a positive deflection in the SCC is 
either anion secretion (from blood to CSF) or cation absorption (CSF to blood) and a negative 
deflection indicates the opposite. TER is recorded every 200 seconds throughout each experiment 
by applying a 2 mV pulse and using the resulting deflection in the SCC to calculate the TER and 
conductance by Ohm’s law. Cultures that showed basal TERs of less than 500 Ω.cm2 were not 
used.   Conductances were also calculated from the change in SCC during the voltages pulses as 
∆I/∆V.  In all cases, the graphs shown in each panel represent a series of control and experimental 
cultures that were grown and analyzed in parallel. 
 
Immunostaining: PCP-R cells were grown to confluency on Transwell filters (9-12 days).  Cells 
were treated with diluent or the TRPV4 agonist GSK101679A for 10 minutes and then 
immediately fixed with 4% paraformaldehyde in PBS. For immunohistochemistry, the fixed cells 
were washed and incubated overnight with anti-claudin-1 primary antibody (Abcam ab15098; 
1:200 dilution) diluted in blocking solution (PBS, 1% goat serum, 1% BSA, 0.1% sodium azide) 
at 4°C. The cells were then washed and incubated with secondary antibody. The secondary 
antibody was Alexa Fluor dye-conjugated goat anti-rabbit (Jackson ImmunoResearch 111-545-
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144, 1:1000 dilution in blocking solution). For nuclear staining DAPI (500 ng/ml; Sigma D9542) 
was used. Confocal images were taken on a Leica TCS SP8 (upright high-speed multiphoton and 
confocal imaging system).  
 
RT-PCR: PCP-R cells were grown as a monolayer in a 75 cm2 flask in PCP-R media until confluent. 
Total RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany), according to the 
manufacturer’s supplementary protocol for animal cells grown in a monolayer. 5 µg of total RNA 
was transcribed to cDNA using the Superscript IV First-Strand Synthesis System (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s protocol using both random hexamers and oligo-
dT primers. Specific primers were designed using Primer3Plus according to mRNA sequences 
obtained from Ensembl and verified using the NCBI database. cDNA was then used for PCR 
utilizing GoTaq Green Master Mix (Promega, Madison, WI) and 10 µM forward and reverse 
primers (IDT, Coralville, IA) (Table 3.1) and the products separated on a gradient agarose gel to 
determine optimum annealing temperatures. A second PCR was carried out using only optimum 
annealing temperatures for each primer pair. Electrophoresis was carried out on a 1.5% agarose 
gel stained with ethidium bromide utilizing flanking 1 kb and 100 bp ladders and visualized under 
UV light using a ChemiDoc XRS imager (Bio-Rad, Hercules, CA). The primers used are shown 
in Table 3.1.  
 
Statistics: All results shown are displayed as mean ± S.E.M. for the number of experiments 
indicated on the graphs. Indicated plot points on all figures were compared using Two-tailed 
Students t-test. P-values less than 0.02 were considered significant. All statistical analyses were 
performed using SigmaPlot 13.0.  
2.6 Results 
The PCP-R cell line develops a high resistance monolayer when grown on permeable supports 
with optimal resistances occurring 9-12 days post seeding (Figure 3.1). Addition of the TRPV4 
agonist GSK1016790A to PCP-R cells causes an increase in transepithelial conductance indicating 
an increased permeability across the epithelial monolayer (Figure 3.2, top).  Concurrently with the 
initiation of the conductance change is a stimulation of short circuit current (SCC) indicating net 
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electrogenic transepithelial ion flux composed of anion absorption (CSF to blood) and/or cation 
secretion (blood to CSF) (Figure 3.2, bottom).  Although the conductance remains elevated, the 
net electrolyte flux returns to a level that is statistically equal to the basal level within 20-30 
minutes after agonist addition.  A 10 minute pre-treatment with either of two structurally unrelated 
TRPV4 antagonists, HC067047 or RN1734, completely blocked the increased permeability of the 
monolayer as well as the electrogenic ion flux (Figure 3.2). To determine the maximal 
concentration of the agonist which did not result in an irreversible change in conductance and ion 
flux, a dose response was performed using concentrations of 0.1, 1, 3, 5, and 10 nM GSK1016790A 
(Figure 3.3). When the TER of the epithelial monolayer falls below 100 Ω*cm2 or the conductance 
rises higher than 10 mS/cm2 it is observed that the TER will continue to fall to unmeasureable 
levels and the experiment using this culture has to be discarded (data not shown). 
 
A limited dose response was also performed for the TRPV4 antagonist RN1734 at concentrations 
of 5, 25, and 50 µM in order to determine the maximal inhibitory concentration (Figure 3.4). 
Interestingly, the agonist-induced conductance responses are immediately reversible upon the 
addition of a TRPV4 antagonist.  This reversal is accompanied by a statistically significant change 
in the electrogenic flux (Figure 3.5). 
 
To visualize how the TRPV4 agonist was affecting the junctional complexes, PCP-R cells grown 
on Transwell filter supports were treated with GSK1016790A or diluent for 10 minutes before 
fixation and staining with anti-claudin-1 antibody (Figure 3.6).  During the incubations, the Ca2+ 
concentration was maintained by the use of serum-free media because changes in extracellular 
Ca2+ have profound effects on tight junctions and epithelial conductance (13,19).  The untreated, 
agonist treated, and negative control (no primary antibody) cells were grown in the same 6-well 
Transwell plate and were treated, fixed, stained and imaged in parallel.   No obvious difference 
was observed between the junctional complexes in any of the monolayers examined; rather all 
junctional complexes remained intact. 
 
Stimulation of TRPV4 causes an influx of Ca2+ which is postulated to secondarily stimulate Ca2+-
activated channels.  Therefore primers were designed to determine the presence of Ca2+-activated 
K+ channels in the PCP-R cell line.  When negative results were obtained, a second primer pair 
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was designed to confirm the results (Table 3.1).  The only Ca2+-sensitive K+ channels found in the 
PCP-R cell line were the intermediate conductance (IK; KCa3.1) and the small conductance (SK) 
2 channels (Figure 3.7).    As expected, TRPV4 is endogenously expressed in the cell line (Figure 
3.7). 
 
The RT-PCR results were followed by electrophysiological experiments. As expected from the 
PCR results, iberiotoxin, an inhibitor of big conductance potassium channels (BK; KCa1.1) had no 
effect on the TRPV4-stimulated conductance change or transepithelial ion flux (Figure 3.8).  
Unexpectedly, apamin, a pan-SK channel blocker, was also without effect on TRPV4-mediated 
ion flux or conductance changes (Figure 3.9).  A similar lack of effect on either 
electrophysiological parameter was noted after pre-incubation with the more SK2-specific 
inhibitors tamapin, Lei-Dab, or scyllatoxin (data not shown). 
 
Pre-treatment with low dose (1 µM) TRAM 34, an inhibitor of two of the three isoforms of IK, 
also termed Kcnn4, had no effect on the subsequent response to TRPV4 agonist. However, 
increasing the TRAM 34 concentration to 50 µM resulted in an inhibition of both the increased 
conductance and short-circuit current (Figure 3.10).   If a moderately high dose of TRAM 34 (25 
µM) was added to the apical bathing media during the pre-incubation, the response to the TRPV4 
agonist was completely inhibited; conversely if the same concentration was added only to the 
media bathing the serosal face of the tissue, there was a reduced inhibition of the ion flux 
accompanied by a substantial, but not complete, inhibition of the increased conductance (Figure 
3.11). 
2.7 Discussion 
Choroid plexus cell line models should be expected to have a phenotype characteristic of epithelia 
that maintain controlled movement of electrolytes and fluid.  In the initial description of the PCP-
R cell line, the cultures developed a transepithelial resistance of 300-600 Ω.cm2 after 6 days of 
culture on permeable supports depending on seeding density (25).  In the current studies, additional 
days in culture resulted in monolayers that exhibited even tighter epithelia, more suitable for 
electrophysiological experiments.  
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In preliminary studies, TRPV4 antagonists decrease hydrocephalic development in a genetic rat 
model of the disease suggesting a role for TRPV4 in CSF secretion (8). As in the native CP (33), 
the PCP-R cells contain TRPV4 which can be activated by a specific TRPV4 agonist.  The 
electrophysiological changes elicited by the TRPV4 agonist are inhibited by two structurally 
distinct and specific antagonists which underscores the specificity of the response.   
 
The rapid and substantial increase in transepithelial conductance elicited in response to the TRPV4 
agonist was unexpected and indicates a large change in transcellular permeability. The 
conductance plateaus at a high level indicating that the permeability remains increased even though 
the electrogenic ion flux returns toward basal levels by 20-25 minutes.  Similar large conductance 
changes have previously been described in colonic epithelia, another epithelium capable of large 
secretory fluxes, after stimulation with prostaglandins (15).  In the PCP-R cells, both the increased 
permeability and stimulated ion flux are immediately reversible by TRPV4 antagonists even after 
the initiation of a response. 
 
TRPV4 has been previously reported to regulate the integrity of the blood-CSF barrier (20). 
However, these studies are difficult to compare to the current experiments because the starting 
resistances of the primary cultures used were low (50-70 Ω.cm2) and treatment with 10 nM 
GSK1016970A caused a disintegration of the cell junctions within 10-20 minutes.  Activation of 
TRPV4 by the phorbol ester 4α-PDD (4α-phorbol-12,13-didecanoate) also caused a decrease in 
transepithelial resistance (increased conductance) in a mammary epithelial cell line similar to the 
change seen in the PCP-R cells (23).  In the latter phase of mammary cell response there was down-
regulation of junctional claudins and frequent large breaks in the tight junction strands.  
 
A dose response using the TRPV4 agonist GSK1016790A in the PCP-R cell line indicated that 
while 5 and 10 nM elicited stronger responses, treatment of PCP-R cells with 3 nM GSK1016970A 
caused no overt changes in the cell junctions and did not cause an irreversible disruption of the 
epithelial structure in confluent monolayers. To mimic a physiologically relevant response, 3 nM 
agonist was used in the majority of the experiments. 
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A dose response was performed using the TRPV4 antagonist RN1734, at concentrations of 5, 25 
and 50 µM, clearly indicating that while concentrations of both 25 and 50 µM caused complete 
inhibition of the change in conductance, 50 µM had the more complete inhibition of the change in 
SCC with no adverse effects on cellular viability as measured by TER (conductance).  
 
Claudin-1, endogenously present in both native CP (12, 14, 29) and the PCP-R cell line (25 and 
Figure 3.2), is considered a barrier claudin important for maintenance of transepithelial 
permeability (14). The immunolocalization of claudin-1 did not change after stimulation with 
GSK1016970A, a finding which is consistent with the rapid reversal of the TRPV4 agonist-
mediated response by antagonist. Both findings suggest that, under our experimental conditions, 
the junctional complexes are not irreparably broken. 
 
Taken together, our results are consistent with a change in transepithelial permeability that does 
not involve the breakdown of tight junctions, the dissociation of the epithelial cells, or a decrease 
in claudin-1 expression in the tight junctions. The reasons for the difference between the current 
studies and the previous reports showing a breakdown of junctional complexes is unknown but the 
agonist concentration may play a role. Over-activation of TRPV4 by exogenous agonists does have 
pathological consequences. For example, i.v. administration of GSK1016790A caused circulatory 
collapse in mice, rats and dogs due to endothelial barrier function failure (33).  While the current 
studies did not explore the long term effects on the junctional complexes, it is important to consider 
the normal in vivo role of TRPV4.  It is unlikely that the endogenous regulation of the channel will 
lead to catastrophic breakdown of tight junctions. GSK1016970A has been shown to have 
nanomolar potency with EC50s between 1-5 nM in human, dog and bovine cellular assays and 
EC50s of 10-18.5 nM in rodents (33). The PCP-R cells are exquisitely sensitive to the agonist with 
~50% of cultures resulting in an irreversible change in conductance at both 5 and 10 nM. The 
maximum agonist concentration that does not result in an irreversible change in 
resistance/conductance appears to be 3 nM and we have chosen, therefore, not to use higher 
concentrations in the majority of the experiments.  
 
When examining the transepithelial ion fluxes using short-circuit current electrophysiology, the 
initial direction of the TRPV4-mediated ion flux is consistent with anion absorption and/or cation 
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secretion.  Given that the CP is, on a per gram basis, one of the most secretory epithelia in the 
body, it is likely that cation secretion accounts for the majority of the electrolyte flux within the 
first few minutes.  Thereafter the net transport indicated by the SCC plateaus briefly and then 
reverses indicating a complex mixture of net electrogenic fluxes.   
 
Although Na+ secretion cannot be discounted, amiloride, an inhibitor of the epithelial Na+ channel 
found in many high-resistance epithelia, did not block the TRPV4-mediated flux (data not shown).  
The role of other Na+ transporters was not examined in these studies.  TRPV4 is a cation channel 
that, when activated, transports Ca2+ into cells. The most likely candidate for the cation secretion 
was postulated to be K+ channels, specifically Ca2+-activated K+ channels.  The importance of 
Ca2+-activated K+ channels in CP epithelia has been recognized for over three decades (17) but the 
identification has remained elusive. RT-PCR of the PCP-R cells indicated the presence of SK2 and 
IK but not SK1 SK3, or BK.  In agreement with these data an inhibitor of BK (iberiotoxin) did not 
block the TRPV4-stimulated changes in transepithelial ion flux or conductance in the PCP-R cell 
line.  While the SK channels are differentially sensitive to apamin, 100 nM of this bee venom 
should have blocked the all three channels (32).  However, pretreatment with apamin did not block 
the TRPV4-mediated ion flux or conductance change.  Likewise, preincubation with tamapin, Lei-
Dab7 or scyllatoxin, relatively specific inhibitors of SK2 (1, 32) did not inhibit GSK1016790A-
stimulated electrogenic ion flux or conductance (data not shown).  Thus, although SK2 appears to 
be present in the cell line, it is not involved in TRPV4 agonist-stimulated ion flux or conductance 
changes. 
 
IK, also known as KCNN4, has recently been shown to have 3 isoforms in the rat.  KCNN4a-
specific transcripts were found in smooth muscle while KCNN4b and KCNN4c were expressed in 
epithelial cells (3).  Interestingly, these latter two isoforms show a divergence in TRAM34 
sensitivity as well as epithelial cell polarity.  In intestinal cells, the IC50 for the inhibitory effect of 
TRAM34 on the KCNN4b isoform was in the sub-micromolar range while the IC50 for the 
KCNN4c isoform was approximately an order of magnitude higher in the low micromolar range 
(3, 4, 15).  The KCNN4b isoform was localized to the basolateral membrane of intestinal cells 
where it was involved in K+ absorption while the KCNN4c isoform was localized to the apical 
membrane where it is involved in K+ secretion (4, 15, 28).   
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Low dose (1 µM) TRAM34 did not affect TRPV4-stimulated ion flux or conductance while 50 
µM completely inhibited both parameters.  These data are consistent with the involvement of the 
Kcnn4c isoform of the IK channel.  A moderately high dose of TRAM34 (25 µM) completely 
inhibited TRPV4-mediated ion flux and conductance changes when added to the apical bathing 
media indicating an apical localization of this isoform as found in previous studies (4, 15, 28).  
However, addition of the same concentration of the inhibitor to the serosal bathing media partially 
inhibited TRPV4-mediated ion flux and substantially, but not completely, blocked the increase in 
conductance.  These data indicate a relatively complex inhibitor effect that could be due to 
transepithelial permeability of the TRAM34 or to off-target effects of the inhibitor. In immune 
cells, micromolar concentration of TRAM-34 reduced lysophosphatidylcholine induced increases 
in intracellular calcium by inhibiting non-selective cation channels (24). Similar effects on non-
selective cation channels, including TRPV4, cannot be ruled out in the current experiments. Figure 
3.12 contains a diagram of the choroid plexus and the hypothesized placement of the IK channel 
based on the current studies.  Additional experiments will be necessary to clarify additional 
components that are likely to be contributing to the electrophysiological responses. 
 
In the 1980’s, a series of elegant electrophysiological experiments by Wright and colleagues in 
Necturus CP showed that the apical membrane accounted for more than 90% of the K+ 
conductance of the epithelial cells and suggested the presence of an apical Ca2+-activated K+ 
channel (17, 37) .  Our current studies are in agreement with this early work and suggest that the 
apical Ca2+-activated K+ channel is the KCNN4c isoform of IK. 
 
In summary, we have shown that activation of TRPV4 stimulates a striking change in 
transepithelial permeability accompanied by a transepithelial ion flux.  The effect of the TRPV4 
agonist appears to be specific because the effect is blocked by two chemically distinct antagonists.  
The lack of permeability change after antagonist pre-incubation further indicates that the agonist 
is not having a nonspecific effect on the epithelial cell junctions. Agents that block the increase in 
conductance also block the electrogenic transepithelial ion flux.  We hypothesize that the 
transepithelial ion flux is due to cation secretion because a preliminary study has indicated that 
TRPV4 antagonists are effective in decreasing the hydrocephalus in a model of the communicating 
form of the disease (8), thus suggesting that electrolyte flux into the CP is an integral component 
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of the response. A substantial portion of the transepithelial ion flux due to stimulation of a Ca2+-
activated K+ channel, IK.  The decreased sensitivity and the apical localization of the TRAM34 
effect in the CP cells indicates that the form of IK found in the CP is KCNN4c.  However, the 
sustained conductance change suggests that the response to TRPV4 stimulation is complex, likely 
involving electrogenic and electroneutral transporters.  Further experimentation will be necessary 
to determine the exact nature of the osmolyte permeability and which transport effects are primary 
and which are secondary. 
2.8 Acknowledgements 
The authors would like to thank Dr. Nicolas Berbari for help in designing the RT-PCR primers.  
2.9 Grants 
These studies were supported by a Hydrocephalus Association/ Team Hydro Innovator Award; 
pilot funding from the Indiana University Collaborative Research Grant Funds of the Office of the 
Vice President for Research; and a Project Development Team within the ICTSI NIH/NCRR grant 
# ULITR001108. 
2.10 Disclosures 
None. 
  
 
 
49 
Table 2.1 Primer Pairs Used for RT-PCR with Corresponding Product Sizes (bp). 
To confirm the presence or absence of the gene of interest for the K+ channels, two different 
primer pairs were used. Gapdh was used as a positive control in all RT-PCR experiments. 
 
Sus 
Scrofa 
gene 
Protein Primer Sequences 5' - 3' Product 
Size 
(bp) 
Forward Primer Reverse Primer 
Kcnn1 SK1 GGAAGAGGAAGAAGATGAGGAA GAGAGGAAAGTGATGGAGATGA 801 
  SK1 CTTCAGCATCTCCTCCTGGATC TGGATGGCTTGGAGGAACTTAC 432 
Kcnn2 SK2 AGAACCAGAATATCGGCTACAA TAAAAGCATGACTCTGGCAATC 488 
  SK2 TCTGATTGCCAGAGTCATGCTT CACGTGCTTTTCTGCTTTGGTA 418 
Kcnn3 SK3 AACACACAAAGCTGCTAAAGAA TCTGGAGTGGGGAGTTTTATTT 466 
  SK3 GGCGAGTACAAGTTCTTCTGGA TAGCTTGCAGGAACTTCCTCTG 685 
Kcnn4 IK CTGGTTTGTGGCCAAGTTGTAC TCCTACGCGTGTGTTTGTAGAA 419 
  IK ATCAGCATTTCCACGTTCTTGC TCCTACGCGTGTGTTTGTAGAA 799 
Kcnma1 BK ACTTGGAAGGAGTCTCAAATGA ATCTGATCATTGCCAGGGATTA 445 
  BK TTACTGCAAGGCCTGTCATGAT AAGGTCCGTATCAGGGTAAGGA 990 
Trpv4 TRPV4 AGATTGGGATCTTTCAGCACAT AGCAAGTAGACCAGCAGGAAAC 724 
Gapdh GAPDH TTTTAACTCTGGCAAAGTGGAC CATTGTCGTACCAGGAAATGAG 884 
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Figure 2.1 Development of Transepithelial Resistance of the PCP-R Cell Line.  
Development of transepithelial resistance of the PCP-R cell line after seeding on Transwell 
supports. The bars are a composite of control values from multiple electrophysiological 
experiments conducted over a two-year period.  In each case the resistance was measured just 
before the addition of an electrolyte transport effector, i.e., after the cells were mounted in the 
Ussing chambers and allowed to reach a stable baseline current.  The bars represent the mean 
+S.E.M. for the number of experiments listed. 
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Figure 2.2: Effect of TRPV4 agonist and antagonists on transepithelial conductance and 
electrogenic ion flux in the PCP-R cell line.   RN1734 or HC067047, specific TRPV4 
antagonists were added to the PCP-R cultures indicated by the open circles and grey squares at 
time T = -10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added to all cultures.  
The symbols represent the means + S.E.M. for the number of experiments indicated on the 
graphs. SCC = short-circuit current. * indicates statistically significant differences between the 
two conditions (p < 0.02) as measured by Students t-test, paired data. 
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Figure 2.2 Effect of TRPV4 Agonist and Antagonists in the PCP-R Cells. 
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Figure 2.3: Dose response for the TRPV4 agonist GSK1016790A effect on transepithelial 
conductance and ion movement in the PCP-R cell line. Concentrations of 0.1, 1, 3, 5, and 10 
nM GSK1016790A were added to the PCP-R cultures at T = 0 minutes. Cell cultures whose 
resistance drops below 100 Ω*cm2 or the conductance rises higher than 10 mS/cm2 were 
considered irreversibly altered by the agonist and were not included. The same experimental 
data were used for both graphs. Delta (∆) SCC is defined as the difference in SCC between the 
value just before agonist addition and the value at the point of the maximal response  The 
symbols represent the means + S.E.M. for the number of experiments indicated on the graphs. 
SCC = short-circuit current. 
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Figure 2.3 Dose Response for TRPV4 Agonist GSK1016790A in PCP-R Cells. 
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Figure 2.4: Dose response for the TRPV4 antagonist RN1734 pre-treatment in the PCP-R cell 
line. Concentrations of 5, 25, and 50 µM RN1734 were added to the PCP-R cultures at T = -
10 minutes. At time 0, the TRPV4 agonist GSK1016790A was added to all cultures. The 
symbols represent the means + S.E.M. for the number of experiments indicated on the graphs. 
SCC = short-circuit current. 
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Figure 2.4 Dose Response for TRPV4 Antagonist RN1734 Pre-Treatment in PCP-R Cells. 
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Figure 2.5: Reversibility of a TRPV4 agonist response by a TRPV4 antagonist.  At time 0 the 
TRPV4 agonist GSK1016790A was added to all culture.  RN 1734, a TRPV4 antagonist, was 
added to the cultures indicated by the open circles 15 minutes after the addition of the agonist. 
The symbols represent the means + S.E.M. for the number of experiments indicated on the 
graphs. SCC = short-circuit current.  * indicates statistically significant differences between 
the two conditions as measured by a 2-tailed Student’s t-test (p < 0.02). 
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Figure 2.5 Reversibility of a TRPV4 Agonist Response by a TRPV4 Antagonist.  
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Figure 2.6 Immunohistological Staining of Claudin 1 in the PCP-R Cell Line. 
Cells were stained with DAPI (blue) to visualize nuclei and anti-claudin-1 antibody (green) to 
show the presence of tight junctions. Treated cells were pre-incubated with TRPV4 agonist, 
GSK1016790A (3nM), for 10 minutes before fixation and staining. Negative control cells were 
stained with DAPI and secondary antibody only. This figure is representative of 4 independently 
conducted experiments. Scale bars represent 25µm. 
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Figure 2.7 RT-PCR of Selected Ion Channels in the PCP-R Cell Line. 
Left hand gel shows the results of RT-PCR of Ca2+-activated K+ channels.  The gel shows 
expression of only SK2 and IK among the calcium activated potassium channels.  SK1, SK3 and 
BK were all notably absent. The second gel shows expression of TRPV4  For any channels not 
present, additional primer sets were utilized to confirm absence of the cDNA.  
SK = small conductance K+ channel; IK = intermediate conductance K+ channel; BK = big 
conductance K+ channel; TRPV4 = transient receptor potential vanilloid 4; GAPDH = 
glyceraldehyde 3-phosphate dehydrogenase  
 
 
 
61 
Figure 2.8: Effect of pre-treatment with a BK channel inhibitor on TRPV4 agonist stimulated 
increases in transepithelial conductance and ion transport.  Iberiotoxin, an inhibitor of big 
conductance potassium (BK) channel was added to the PCP-R cultures indicated by the open 
circles at time T = -10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added to 
all cultures.  The symbols represent the means + S.E.M. for the number of experiments 
indicated on the graphs. SCC = short-circuit current. 
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Figure 2.8 Effect of BK Channel Inhibitor on TRPV4-Mediated Responses. 
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Figure 2.9: Effect of pre-treatment with an inhibitor of SK channels on TRPV4 agonist 
stimulated increases in transepithelial conductance and ion transport. Apamin, an inhibitor of 
small conductance potassium (SK) channels, was added to the PCP-R cultures indicated by the 
open circles at time T = -10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added 
to all cultures.  The symbols represent the means + S.E.M. for the number of experiments 
indicated on the graphs.  SCC = short-circuit current. 
 
 
 
64 
Figure 2.9 Effect of SK Channel Inhibitor on TRPV4-Mediated Responses. 
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Figure 2.10: Effect of pre-treatment with high and low doses of an IK channel inhibitor on 
TRPV4 agonist stimulated increases in transepithelial conductance and ion transport. 
TRAM34, an inhibitor of intermediate conductance potassium (IK) channels, was added 
bilaterally to the PCP-R cultures indicated by the open circles or inverted triangles at time T = 
-10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added to all cultures.  The 
symbols represent the means + S.E.M. for the number of experiments indicated on the graphs.  
SCC = short-circuit current.  The positive control data (GSK1016790A only) shown in this 
figure are the same data that are shown in figure 11. * indicates statistically significant 
differences between the experimental and control (solid circles) groups (p < 0.02) as measured 
by Students t-test, paired data. τ indicates statistically significant differences between the two 
experimental (open circles and inverted triangles) groups (p < 0.02) as measured by Students 
t-test, paired data. 
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Figure 2.10 Effect of High/Low Doses of IK Inhibitor on TRPV4-Mediated Responses. 
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Figure 2.11: Sidedness of the effect of an inhibitor of IK channels on TRPV4 agonist stimulated 
increases in transepithelial conductance and ion transport. TRAM34, an inhibitor of 
intermediate conductance potassium (IK) channels, was added to either the serosal or apical 
bathing media of the PCP-R cultures indicated by the open circles or inverted triangles at time 
T = -10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added to all cultures.  The 
symbols represent the means + S.E.M. for the number of experiments indicated on the graphs.  
SCC = short-circuit current.  The positive control data (GSK1016790A only) shown in this 
figure are the same data that are shown in figure 10. * indicates statistically significant 
differences between the experimental and control (solid circles) groups (p < 0.02) as measured 
by Students t-test, paired data. τ indicates statistically significant differences between the two 
experimental (open circles and inverted triangles) groups (p < 0.02) as measured by Students 
t-test, paired data. 
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Figure 2.11 Sidedness of IK Channel Inhibitor on TRPV4-Mediated Responses.  
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Figure 2.12 Diagram of Selected Transporters in the Choroid Plexus Epithelia. 
The left hand side of the diagram illustrates that the choroid plexus within the ventricle is 
continuous with the ependymal cells. Choroid plexus cells (dark purple) are increased in size 
compared to ependymal cells (light purple). On the right-hand part of the diagram, individual 
choroid plexus cells are shown as polarized with transporters on both the apical and basolateral 
membranes, and connected by tight junctional proteins.  
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 THE ROLE OF NKCC1 AND SPAK IN TRPV4-
MEDIATED TRANSPORT 
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SPAK, as well as the final formatting for all electrophysiology figures. Keith Gafunderi 
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3.3 Abstract 
Cerebrospinal fluid (CSF) is produced primarily by the choroid plexus (CP), a network of secretory 
epithelial cells surrounding a fenestrated capillary bed. The CP establishes a barrier between the 
blood and CSF, maintaining a gradient which allows for secretion of ions and fluid, thus producing 
CSF. Transient Receptor Potential Vanilloid-4 (TRPV4) is a non-selective cation channel which 
has been shown to stimulate transepithelial ion flux in CP cells. Using the porcine choroid plexus 
-Riems (PCP-R) cell line, we have investigated the role of the Na+-K+-2Cl- (NKCC1) cotransporter 
in TRPV4-mediated electrogenic ion flux. The acute changes in short circuit current (SCC) as well 
as transepithelial conductance stimulated in response to TRPV4 activation were not affected by 
bumetanide, a specific inhibitor of NKCC1. Prolonged inhibition of NKCC1 also resulted in no 
significant changes to the transcription of TRPV4 or STE20/SPS1-related proline/alanine rich 
kinase (SPAK), a regulatory kinase known to phosphorylate and activate NKCC1. However, 
inhibition of SPAK with the specific inhibitor, STOCK2S-26016, inhibited both the transepithelial 
ion flux and barrier permeability changes associated with TRPV4 stimulation. Finally, extended 
24 hour inhibition of SPAK resulted in increased transcription of TRPV4. These studies suggest 
that TRPV4 may be regulated via SPAK but independent of the established NKCC1 mechanism 
of homeostatic and volume regulation. 
3.4 Introduction 
The choroid plexus (CP) is thought to be the primary tissue responsible for the production of 
cerebrospinal fluid (CSF) in the brain. Located in the lateral, third, and fourth ventricles, the CP 
consists of a branching network of epithelial cells surrounding a fenestrated capillary bed (6-
8,29,33,40,46). CP epithelial cells are responsible for regulating the movement of water and small 
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molecules through the use of ion channels, transporters and aquaporins, resulting in the production 
of 500 to 600 ml of CSF per day in adult humans (5,29,46). Evidence suggests that up to 80% of 
CSF is produced by the CP (4,5,40). The remainder is thought to be produced by the ependymal 
epithelial cells lining the ventricles, which are contiguous with the CP epithelia, in addition to cells 
lining the subarachnoid space (4,46). CSF is responsible for cushioning the brain and protecting it 
from injury by reducing the effective weight of the tissue from 1500 grams to approximately 50 
grams, by virtue of buoyancy (4,5,46). Additionally, it is thought to play a key role in waste and 
toxin clearance from the central nervous system, tightly controlled by the sleep-wake cycle (13). 
However, little is understood about the control mechanisms by which the CSF is produced, 
absorbed and regulated.  
 
It has been previously demonstrated that Transient Receptor Potential Vanilloid-4 (TRPV4) may 
play a role in the transepithelial movement of ions across the blood-CP barrier, thereby altering 
the production of CSF (41,45). TRPV4 is a nonselective cation channel, which has been shown to 
transport small ions including sodium, potassium and calcium (3,28,30,36,42,48). TRPV4 is 
widely expressed in lung and gut epithelia, as well as in the kidney and various brain regions, 
including the hippocampus, dorsal root ganglion, neurons, and the CP (9,28,36,42,48). Localized 
on the apical membrane of CP epithelial cells, TRPV4 is a mechano- and osmo-sensitive hub 
protein that may act to direct ion transport events responsible for the regulation of CSF production 
(36,41).  
 
A potential link between TRPV4 and the electroneutral Na+-K+-2Cl- cotransporter (NKCC) has 
been explored previously in the hippocampus in brain edema following traumatic brain injury 
(TBI). In this study, it was shown that NKCC1 is necessary for TRPV4 activation in the 
hippocampus, which leads to activation of the MAPK signaling cascade (32). Belonging to the 
SLC12 family of cotransporters, NKCC is expressed as either NKCC1 or NKCC2. NKCC2, 
encoded by the gene SLC12A1, is localized primarily in the thick ascending limb of renal tubules 
and is thought to be kidney specific (2,21). NKCC1 is more widely expressed in transporting 
polarized epithelia and is typically found localized to the basolateral membrane (2,21,26). In the 
CP, however, NKCC1 has been identified as being on the apical membrane (20,27,34,39,47). 
Several studies have demonstrated that NKCC1 is one of the transporters responsible for 
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establishing the electrochemical gradient across the CP and for maintaining the driving forces 
necessary for CSF secretion (8,11). Interestingly, Gregoriades et al. showed that the net direction 
of NKCC1 transport in the CP may be either inward or outward, depending on the intracellular 
concentrations of Na+, K+, and Cl- and the kinetics of this reversal were demonstrated by Delpire 
and Gagnon (11,20). This suggests that NKCC1 is capable of responding to a variety of 
physiological conditions and thusly directing the net flow of ions across the CP epithelia. The 
SLC12 family also contain the four potassium-chloride cotransporters (KCC1-4). These 
cotransporters are thought to work exclusively in the net efflux direction and have been identified 
on both the apical and basal membranes of secretory epithelia (5,7). 
 
Ste20/SPS1-related proline/alanine rich kinase (SPAK) is responsible for modulation of various 
biological processes (12). SPAK is an evolutionarily redundant kinase for OSR1, which also acts 
through a mechanism called the WNK-SPAK/OSR1 pathway. WNK kinases have been 
demonstrated to phosphorylate and activate SPAK, which in turn is responsible for 
phosphorylation and activation of downstream targets. One such target is NKCC1 which, when 
phosphorylated, results in activation of the cotransporter (1,2,10-12,15-17,19-23,26,35,37,38,43). 
As the movement of ions via NKCC1 also allows for the transepithelial movement of water, this 
regulation of NKCC1 may play a significant role in cell volume homeostasis (2,21). Additionally, 
the WNK-SPAK/OSR1 pathway also regulates the KCCs via phosphorylation (12,23). However, 
in contrast to the NKCCs, phosphorylation of the KCCs by the WNK-SPAK/OSR1 pathway 
results in inhibition (12,22,23,43). Studies have shown that TRPV4 may be regulated in part by 
WNK4 (18). However, thus far, no interactions have been proven between TRPV4 and SPAK. 
 
The porcine choroid plexus -Riems (PCP-R) cell line has previously been utilized as an in vitro 
model of CP function and expresses a variety of ion channels and transporters found in in vivo 
(41,44,45). Exhibiting many distinct characteristics of CP epithelium, the PCP-R cell line consists 
of a high resistance monolayer epithelium and expression of tight junctional proteins, including 
claudins and occludins. We have previously used this model to study the role of TRPV4 in 
transepithelial ion transport across the CP (41,45).   
 
 
 
78 
In this study, we investigate the interactions between TRPV4, NKCC1, and the regulatory WNK 
kinase, SPAK, in the PCP-R cell line. From these studies, we hope to establish a better 
understanding of the role of TRPV4 in CSF regulation and the mechanisms behind it.  
3.5 Methods and Materials 
Cell Culture: PCP-R cells were seeded on 6-well cluster plates containing 0.4 µM filter diameter 
polycarbonate permeable bottom supports (Corning Life Sciences, Lowell, MA; #3412) for 
approximately 10-12 days, until cell cultures achieved a transepithelial resistance (TER) >500 
Ωcm2. Cultures below 500 Ωcm2 were not considered high resistance and were not used for 
experiments. Additionally, cultures whose TERs dropped below 100 Ωcm2 during the time course 
of the experiments were also not used, due to irreversible changes in the tight junctions. PCP-R 
cell cultures were grown using DMEM (Gibco, Gaithersburg, MD; #12100-046), with 4.5 g/L 
glucose, 3.7 g/L NaHCO3, 24 mM HEPES, 10% fetal bovine serum (Atlanta Biologicals, Flowery 
Branch, GA), 100 U/ml penicillin, 100 mg/ml streptomycin, and 5 µg/ml insulin. Cells were bathed 
in 2 ml of the PCP-R media apically (filter top) and 3 ml basolaterally (filter bottom). PCP-R 
media was replaced 3 times weekly. 
 
Electrophysiology: For electrophysiological experiments, PCP-R cells were grown on transwell 
plates until confluent (10-12 days), excised and subsequently mounted in Ussing chambers 
connected to a DVC-1000 Voltage/Current clamp (World Precision Instruments, Sarasota, FL) 
with voltage and current electrodes attached on either side of the membrane. Each side of the 
chamber was bathed in 10 ml of serum free media at 37°C. Media-containing chambers were water 
jacketed to maintain a constant physiological temperature of 37°C. A 5% CO2/95% O2 gas lift 
circulated media through chambers and oxygenated the chamber-mounted cells. The spontaneous 
transepithelial potential difference was clamped to zero, and cells were allowed to equilibrate for 
at least 20 minutes. Experimental compounds were added to the apical and/or basal media, and the 
resulting short circuit current (SCC) was recorded as a measurement of net transepithelial ion 
movement. By convention, a positive deflection of the SCC represents either anion secretion 
(blood to CSF directed movement) or cation absorption (CSF to blood), while the opposite is true 
for a negative deflection. Additionally, a 2 mV pulse was applied every 180 seconds, and the 
resulting change in SCC was recorded. This change in SCC was used to calculate transepithelial 
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resistance (TER) using Ohm’s Law, and the resulting TER values were converted to transepithelial 
conductance by calculating the inverse of the TER. The transepithelial conductance is an indication 
of net ion movement and barrier permeability in cells. A low conductance (<2 mS/cm2) represents 
low net ion movement and a tight barrier. Any increase in the transepithelial conductance is 
observed to be an increase in the transepithelial ion movement and/or increased cellular 
permeability. For all electrophysiological experiments, both the control and experimental groups 
were analyzed simultaneously, as represented in the graphs. 
 
Reverse Transcriptase (RT)-PCR: PCP-R cells were grown to confluence on transwells. The 
monolayers were washed twice with cold 1X PBS, and total cell RNA was collected utilizing the 
Monarch Total RNA Miniprep Kit (New England Biolabs, #T2010S) using the manufacturer’s 
directions for cultured mammalian cells. RNA concentration was measured using an ND2000 
Nanodrop (Fisher Scientific, Waltham, MA). Approximately 100 ng of total RNA was reverse 
transcribed into cDNA using the Monarch LunaScript RT SuperMix Kit (New England Biolabs; 
#E3010L), along with corresponding No-template and -RT controls, according to the 
manufacturer’s directions. Sus Scrofa exon mRNA sequences for each gene were obtained using 
Ensembl, and primer pairs for each were designed using Primer3Plus. Approximately 500 ng of 
template cDNA was combined with the forward and reverse primers (IDT, Coralville, IA), as well 
as GoTaq Green Master Mix (Promega Corporation, Madison, WI; #M7122). Reactions were run 
as a gradient to determine optimum annealing temperature for each primer pair, and products were 
separated on a 1.5% agarose gel with ethidium bromide. Flanking 100 bp ladders were used as 
molecular weight markers, and gels were imaged using a ChemiDoc XRS imager (Bio-Rad, 
Hercules, CA). Single band amplicons of the correct molecular weight were sequenced (Eton 
Biosciences, Union, NJ) and the correct products were validated using NCBI and Ensembl BLAST. 
 
Quantitative (q)PCR: PCP-R cells were grown as previously described until confluent. 24 hours 
prior to mRNA collection, experimental cells were treated with specific compounds both apically 
and basolaterally and allowed to incubate overnight. Cells were washed twice with cold 1x PBS, 
and total RNA was collected using the Monarch Total RNA Miniprep Kit (New England Biolabs) 
according to the manufacturer's directions for cells cultured in a monolayer. The resulting purified 
RNA concentration was measured using an ND2000 Nanodrop (Fisher Scientific, Waltham, MA). 
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100 ng of total RNA was reverse transcribed into cDNA using the Monarch LunaScript RT 
SuperMix Kit (New England Biolabs). The cDNA was then diluted 1:10 with nuclease-free water 
(New England Biolabs). qPCR was performed using a LightCycler 480 Instrument II real-time 
PCR system (Roche LifeScience, Penzberg, Germany), utilzing LightCycler 480 SYBR Green I 
Master Mix (Roche LifeScience, #04707516001). qPCR cycle conditions were 95°C for 5 minutes; 
followed by 45 cycles of 95°C for 10 seconds, 60°C for 10 seconds, and 72°C for 10 seconds. Data 
are displayed as relative fold change in expression using the 2-Δ ΔCT method (31), relative to the 
calibrator housekeeping genes GAPDH and Rps18. Data are shown as fold change of TRPV4 or 
NKCC1 in treated cell cultures relative to the normalized controls. 
 
Statistics: Statistics were calculated using Two-tailed Students t-test in Sigma Plot 13. p < 0.05 is 
considered significant. Students t-test was used to compare experimental groups to the control as 
indicated by the symbols defined in the figure legends. 
3.6 Results 
Three sets of redundant primer pairs per gene were utilized to determine the presence of specific 
genes of interest in the PCP-R cell line using RT-PCR (Table 1). Single band amplicons were 
sequenced to confirm the correct mRNA had been amplified. mRNA encoding for NKCC1 was 
identified in the PCP-R cells, as well as mRNA for all four KCC cotransporters (KCC1-4) (Figure 
1). NKCC2 is typically thought to be a kidney-specific isoform, primarily found in the thick 
ascending limb, while NKCC1 is expressed in nearly all secretory cell types. All 4 KCCs have 
been identified in various parts of the central nervous system, with KCC2 thought to be responsible 
for maintaining low Cl- in neurons (25,50).  Additionally, STK39 mRNA, which encodes for 
SPAK was shown to be present in the PCP-R cells. As previously demonstrated, TRPV4 mRNA 
is also shown to be expressed in the PCP-R cell line. GAPDH was used as an internal positive 
control. 
 
Ussing chamber electrophysiology was used to measure net changes in transepithelial ion flux as 
well as barrier permeability. As previously demonstrated, addition of the TRPV4 agonist 
GSK1016790A stimulates a multiphasic change in SCC, accompanied by an increase in 
transepithelial conductance (41,45). The negative change in SCC is representative of a net 
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electrogenic transepithelial ion transport, which is consistent with either anion absorption and/or 
cation secretion. The positive change in transepithelial conductance is consistent with an increase 
in barrier permeability (41,45). For each subsequent figure, experiments were conducted with 
paired controls, which utilized a vehicle for the pre-incubated effector and the TRPV4 agonist 
GSK1016790A. In each experiment, the TRPV4 agonist was added at time point T = 0 for all 
cultures. For experimental cultures, cells were pre-treated with specific inhibitors or modulators 
10 minutes prior to the addition of the TRPV4 agonist.  
 
Several studies have shown the kinase SPAK to phosphorylate and activate the NKCC 
cotransporters, as well as phosphorylating and inhibiting the KCC channels (1,2,10-12,15-17,19-
21,23,26,35,37,38,43). Therefore, it is heavily involved in the regulation of ion transport and could 
potentially be involved in TRPV4-mediated transport. Pretreatment of the PCP-R cells with a 
SPAK/OSR1 inhibitor, rafoxanide, prior to stimulating TRPV4 with its agonist resulted in a 
significant inhibition of the change in basal transepithelial ion flux. Interestingly, the change in 
cellular permeability showed a rapid increase immediately following the addition of the 
SPAK/OSR1 inhibitor. This increase was statistically significant immediately following inhibition 
of the kinases and remained significantly higher than the control experiment conductance until 
approximately 5 minutes post-addition of the TRPV4 agonist (Figure 2). A second, more specific 
inhibitor of the WNK-SPAK pathway, STOCK2S 26016, was utilized at 10 µM to inhibit the 
kinase. Following pretreatment with STOCK2S, both the SCC and conductance changes normally 
observed upon addition of the TRPV4 agonist were substantially inhibited. However, in these 
experiments, no initial increase in transepithelial conductance was observed upon SPAK inhibition 
alone (Figure 3). 
 
Pretreatment of the PCP-R cells with 100 µM bumetanide, a specific inhibitor of NKCC, on both 
the apical and basolateral membranes 10 minutes prior to the addition of the TRPV4 agonist 
resulted in a statistically significant inhibition of the TRPV4-mediated ion flux during the second 
phase (T = 10-20) of the agonist-induced SCC change (Figure 4). In the CP, NKCC1 has been 
identified on the apical membrane. To determine whether the bumetanide effect was restricted to 
a single membrane, cells were treated on either the apical or the basolateral membranes. When 
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added to only one membrane, 100 µM bumetanide was observed to have no effect on the TRPV4 
agonist-stimulated transepithelial ion flux or permeability changes (Figure 5). 
 
As the KCC ion channels are regulated by the WNK-SPAK/OSR1 pathway similar to the NKCCs, 
we also investigated whether the KCCs are involved in the TRPV4-mediated pathway (12,23). 
Therefore, PCP-R cells were pretreated with 25 µM R-(+)-DIOA, a nonspecific inhibitor of the 
KCC cotransporters, either on the apical or basolateral membrane.  However, treatment with the 
KCC inhibitor had no effect on either the SCC or transepithelial conductance following addition 
of the TRPV4 agonist (Figure 6). 
 
To determine if NKCC and the KCCs acted in concert relative to each other for regulation of 
intracellular [Cl-], cells were co-incubated with a cocktail containing 100 µM bumetanide and 25 
µM R-(+)-DIOA added to both sides of the membrane. No effects on TRPV4-mediated 
transepithelial ion flux nor permeability changes were observed following treatment with the 
TRPV4 agonist (Figure 7). 
 
To determine whether NKCC1 or SPAK inhibition had an effect on gene expression, cultures were 
incubated for 24 hours with 100 µM bumetanide or 10 µM STOCK2S, and mRNA was collected 
for qPCR analysis. The expression of TRPV4, NKCC1 and SPAK mRNA were observed relative 
to their respective expression in parallel control cultures incubated with vehicle only. Incubation 
with bumetanide had no significant effect on mRNA expression of TRPV4, NKCC1 or SPAK 
(Figure 8). 24 hour incubation with the SPAK inhibitor STOCK2S resulted in a net 2-fold decrease 
in NKCC1 and SPAK mRNA expression, while no changes in TRPV4 mRNA were observed 
(Figure 9). 
3.7 Discussion 
NKCC1 is ubiquitously expressed in many secretory epithelia and is thought to be involved in the 
maintenance of cell volume and homeostasis (2,21). In most tissues, it is localized to the basolateral 
membrane (2,21). However, in the CP is has been demonstrated that NKCC1 localizes to the apical 
membrane in CP, a somewhat curious finding (20,34,47). The apical localization of NKCC1 has 
been a cause of significant controversy for several years, with two arguments typically presented. 
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If NKCC1 operates in net efflux mode (not generally found in other tissues), it contributes to the 
production of CSF via the movement of ions from the intracellular space to the intraventricular 
space (11,20,47). Alternatively, if NKCC1 operates in net influx on the apical membrane, then it 
is assumed to contribute to reabsorption of ions into the intracellular space of CP cells, maintaining 
cell volume and homeostasis (2,11,20,21). Evidence exists to support both hypotheses, and a 
rationale has been proposed that suggests NKCC1 is capable of reversing its directionality based 
upon cellular physiological needs as well as on ion gradients of which TRPV4 is capable of 
creating (11,20). 
 
In addition to NKCC1, all four KCC cotransporters have been identified in different regions of the 
central nervous system (24,25,50). Previous reports have suggested that KCC4 and KCC3 may be 
expressed on the apical and basolateral membranes of the CP epithelia, respectively (7,8,25). In 
this tissue, these ion channels are thought to be involved in chloride efflux from the cell; with 
KCC4 contributing to chloride efflux into the CSF, and KCC3 contributing to chloride efflux into 
the blood (7,8,40). Additionally, it has been shown that KCC1 is also present in the CP cells, 
although its localization has not been resolved (24,49). 
 
Following collection of mRNA from cultured PCP-R cells, RT-PCR showed clear expression of 
NKCC1 and all four KCC variants. This was somewhat surprising, as KCC2 has not previously 
been identified in CP. In mouse choroid plexus, Kanaka et al. showed an absence of KCC2 mRNA, 
while KCC1, KCC3 and KCC4 have all been identified in both mouse and rat CP (7,8,24,25,49). 
This channel’s presence in porcine CP epithelia, but absence in rodent CP epithelia may suggests 
species-specific differences in gene regulation. 
 
In regards to the interactions between NKCC1 and TRPV4, the relationship has remained elusive 
for a number of years. One study suggests that TRPV4 is responsible for mediating brain edema 
induced by NKCC1 following traumatic brain injury (TBI) (32). In this study, it was found that 
treatment with bumetanide in TBI-induced brain edema resulted in a reversal of the upregulation 
of TRPV4 expression in the hippocampus following TBI. On the other hand, treatment with the 
TRPV4 inhibitor RN1734 was ineffective towards the expression of NKCC1 following TBI. This 
suggests that NKCC1 regulates TRPV4 expression in the hippocampus. In our experiments, 
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inhibition of NKCC1 with a high dose of bumetanide resulted in a statistically significant 
inhibition of some components ofthe TRPV4-mediated ion flux. However, 100 µM bumetanide 
was shown to have no effect on the resulting increase in transepithelial conductance, which 
remained high in both the experimental and control groups. We then sought to determine whether 
this effect was observed on either the apical or basolateral membrane alone. Treatment with 100 
µM bumetanide on only one side of the membrane, however, resulted in no changes to the resulting 
electrogenic ion flux or conductance.  
 
To ascertain a role for the KCC cotransporters in TRPV4-mediated flux. R-(+)-DIOA, a 
nonspecific pan-KCC inhibitor was used at 25 µM, with no effect observed on either the TRPV4 
agonist-stimulated SCC or conductance changes. This was not entirely unexpected, as the KCCs 
are localized to both membranes, with transport resulting in net efflux of Cl- and K+.    Finally, to 
ascertain whether the KCCs acted in concert with NKCC1, we co-incubated cells with both 100 
µM bumetanide and 25 µM R-(+)-DIOA. Again, as with previous experiments, no effects were 
observed. These data suggest that while NKCC1 and the KCCs may play a role in CP epithelial 
cell homeostasis, it appears they do not in fact regulate TRPV4 activity.  
 
SPAK has been demonstrated to phosphorylate and activate NKCC1, as well as to phosphorylate 
and inhibit the KCCs (12,34,43). Thus far, no direct link between SPAK and TRPV4 has been 
shown. However, anecdotal evidence exists suggesting a role for SPAK in regulating TRPV4 
activity. In the HEK-293 cells, WNK4 expression has been shown to downregulate TRPV4 
function (14,18). WNK kinases regulate SPAK and the redundant kinase OSR1 upstream, which 
suggests a signaling cascade which may perturb TRPV4 function. To address this, we inhibited 
the WNK pathway in PCP-R cells with the SPAK/OSR1 inhibitor, rafoxanide. Upon stimulation 
of TRPV4 with its agonist, we observed a near-complete inhibition of the TRPV4-mediated ion 
flux in the SPAK-inhibited cultures. Interestingly, initial treatment with rafoxanide also resulted 
in an immediate and sustained increase in the conductance, suggesting the WNK pathway plays a 
role in basal ion permeability and cell volume homeostasis, likely through an ion transporter it 
regulates. This change in cellular permeability, upon addition of the TRPV4 agonist closely 
mimicked that of the control experiments. A second, more specific inhibitor of the WNK-SPAK 
activation pathway, STOCK2S-26016, was employed to confirm this result in regards to SPAK. 
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From this, we found no initial conductance increase was observed in the PCP-R cells when SPAK 
phosphorylation was inhibited as compared to inhibition of both SPAK and OSR1. Contradictory 
to the previous result, specific inhibition of SPAK resulted in inhibition of not only the TRPV4-
mediated change in transepithelial ion flux, but also of the change in cellular permeability.  These 
data suggest a regulatory role for SPAK in the TRPV4 pathway with TRPV4-mediated activity 
dependent on the kinase, although the mechanism of this regulation is currently unknown. Taken 
together with the bumetanide results, it appears that the regulatory role of SPAK occurs 
independently of NKCC1 activation, as direct inhibition of NKCC1 did not inhibit TRPV4-
stimulated permeability nor transepithelial ion flux changes to the same degree observed with 
SPAK inhibition. 
 
Previously, bumetanide-induced inhibition of NKCC1 has not to our knowledge been 
demonstrated to effect gene regulation. Following prolonged exposure of the PCP-R cells to 
bumetanide, we have shown that NKCC1 inhibition does not affect the transcription of TRPV4, 
NKCC1 or SPAK. This suggests that a compensatory feedback mechanism does not exist at the 
transcription level in the cells in response to aberrantly regulated NKCC1. Transcription of the 
same genes in PCP-R cells were observed following SPAK inhibition with STOCK2S for 24 hours 
in order to determine the effect on gene regulation. Interestingly, NKCC1 expression decreased 4-
fold following 24 hour inhibition of SPAK. This suggests that SPAK is necessary for both 
transcription and activation of NKCC1, albeit through an unknown mechanism. Additionally, 
TRPV4 mRNA expression was observed to increase 2-fold, while SPAK mRNA expression did 
not appear to change in response to prolonged SPAK inhibition. These data appear to contradict 
the electrophysiological results, suggesting that the inhibition of SPAK actually results in more 
TRPV4. A simple explanation may, however, answer this question. If SPAK inhibition over an 
extended period results in inhibited TRPV4, there may exist a feedback mechanism by which 
TRPV4 is overexpressed to compensate for inactive TRPV4 at the apical membrane.  
 
In summary, inhibition of NKCC1 with bumetanide resulted in moderate inhibition of TRPV4-
mediated transepithelial ion fluxes but did not inhibit increases in conductance associated with 
TRPV4 activation. Our studies show that inhibition of the KCCs had no effect on either TRPV4-
mediatedion transport or conductance changes. Additionally, co-incubation with inhibitors of both 
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NKCCs and the KCCs resulted in no inhibition of TRPV4-mediated activity. We found, however, 
that inhibition of SPAK resulted in inhibition of both the transepithelial ion flux and permeability 
changes associated with activation of TRPV4. Previous data from our laboratory has established 
that transepithelial ion flux and alterations in cellular permeability in CP epithelia are carefully 
regulated via TRPV4. However, we now have shown that SPAK appears to be a significant 
regulator of the TRPV4-mediated ion flux pathway. Although, unexpectedly, this regulation 
appears to be not through regulation of NKCC1. Future experimentation will be necessary to 
elucidate the regulatory role of SPAK for TRPV4 activation and begin to organize the molecular 
orchestra responsible for the production of CSF. 
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Table 3.1 Sus Scrofa Primers Used for RT-PCR with Corresponding Product Sizes (bp).  
Three different primer sets were generated and tested for each gene. Primers included in this table 
were utilized for Figure 1. GAPDH was used as a positive control. 
Sus 
Scrofa 
gene 
Protein Primer Sequences 5' - 3' Product 
Size 
(bp) 
Forward Primer Reverse Primer 
TRPV4 TRPV4 AGATTGGGATCTTTCAGCACAT AGCAAGTAGACCAGCAGGAAAC 724 
Stk39 SPAK TAGCAACAGGGGGTGATGTTAC CTCTTTGGGCTATGTCTGGTGT 432 
SLC12A2 NKCC1 ATTTTCGCGAGGAAGAGACCTT TGCACTCACAAGGGATGCTAAT 428 
SLC12A4 KCC1 TGTACCACCTACGTCTTGAAGC GCACTTCCAGGAACTCCATGTA 495 
SLC12A5 KCC2 CTGGCTTACCTTTTCCCAGCTA TTGGTCAGATAGGAGCTCCAGA 485 
SLC12A6 KCC3 AGGCAGAGAACATCACTGAAGG ATACCACCAACACCATGAGGAC 498 
SLC12A7 KCC4 TTACATGATATCGCGGTCCCTG CAAAATACGGGTCACAGGAGGA 494 
Gapdh GAPDH TTTTAACTCTGGCAAAGTGGAC CATTGTCGTACCAGGAAATGAG 884 
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Figure 3.1 RT-PCR in the PCP-R Cell Line. 
RT-PCR in the PCP-R cell line. mRNA for NKCC1, KCC1-4, TRPV4, and STK39 are present in 
the PCP-R cell line. GAPDH was used as a positive control. 100 bp flanking ladders were used. 
RT = Reverse transcriptase. Lanes denoted as (+) or (-) RT identify the presence or absence of 
reverse transcriptase in the PCR mixture. 
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Figure 3.2: Pre-treatment of PCP-R cells with a SPAK inhibitor prior to addition of a TRPV4 
agonist. Net changes in transepithelial ion flux and conductance were measured. Rafoxanide 
(10 µM) was added both apically and basolaterally at T = -10 minutes. The TRPV4 agonist 
GSK1016790A was added to the basolateral side of the membrane in all cultures at T = 0 
minutes. Pre-incubation with Rafoxanide is represented by white open circles. The GSK-
treated positive controls are denoted by black filled circles. Circles represent mean values, and 
error bars represent +/- SEM for the n indicated. SCC = short circuit current. * = p < 0.05 
against control experiments.  
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Figure 3.2 Effect of SPAK Inhibitor on TRPV4-Mediated Responses.  
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Figure 3.3: Pre-treatment of PCP-R cells with a SPAK inhibitor prior to addition of a TRPV4 
agonist. Net changes in transepithelial ion flux and conductance were measured. STOCK2S 
26016 (10 µM) was added both apically and basolaterally at T = -10 minutes. The TRPV4 
agonist GSK1016790A was added to the basolateral side of the membrane in all cultures at T 
= 0 minutes. Pre-incubation with STOCK2S 26016 is represented by white open circles. The 
GSK-treated positive controls are denoted by black filled circles. Circles represent mean 
values, and error bars represent +/- SEM for the n indicated. SCC = short circuit current. * = p 
< 0.05 against control experiments.  
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Figure 3.3 Effect of SPAK Inhibitor on TRPV4-Mediated Responses. 
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Figure 3.4: Pre-treatment of PCP-R cells with an NKCC inhibitor prior to addition of a TRPV4 
agonist. Net changes in transepithelial ion flux and conductance were measured. Bumetanide 
(100 µM) was added simultaneously to both the apical and basal surfaces at T = -10 minutes. 
The TRPV4 agonist GSK1016790A was added to the basolateral side of the membrane in all 
cultures at T = 0 minutes. Pre-incubation with Bumetanide is represented by white open circles. 
The GSK controls are denoted by black filled circles. Circles represent mean values, and error 
bars represent +/- SEM for the n indicated. SCC = short circuit current. * = p < 0.05 against 
control experiments.  
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Figure 3.4 Effect of NKCC Inhibitor on TRPV4-Mediated Responses. 
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Figure 3.5: Pre-treatment of PCP-R cells with an NKCC inhibitor prior to addition of a TRPV4 
agonist. Net changes in transepithelial ion flux and conductance were measured. Bumetanide 
(100 µM) was added either apically or basolaterally at T = -10 minutes. The TRPV4 agonist 
GSK1016790A was added to the basolateral side of the membrane in all cultures at T = 0 
minutes. Pre-incubation with Bumetanide to the apical or basolateral surfaces is represented 
by white open circles, or grey filled circles, respectively. The GSK-treated positive controls 
are denoted by black filled circles. Circles represent mean values, and error bars represent +/- 
SEM for the n indicated. SCC = short circuit current. * = p < 0.05 against control experiments.  
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Figure 3.5 Sidedness of NKCC Inhibitor on TRPV4-Mediated Responses.  
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Figure 3.6: Pre-treatment of PCP-R cells with a KCC inhibitor prior to addition of a TRPV4 
agonist. Net changes in transepithelial ion flux and conductance were measured. R-(+)-DIOA 
(25 µM) was added either apically or basolaterally at T = -10 minutes. The TRPV4 agonist 
GSK1016790A was added to the basolateral side of the membrane in all cultures at T = 0 
minutes. Pre-incubation with R-(+)-DIOA apically or basolaterally is represented by white 
open circles, or grey filled triangles, respectively. The GSK-treated positive controls are 
denoted by black filled circles. Circles represent mean values, and error bars represent +/- SEM 
for the n indicated. SCC = short circuit current. * = p < 0.05 against control experiments.  
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Figure 3.6 Sidedness of KCC Inhibitor on TRPV4-Mediated Responses.  
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Figure 3.7: Pre-treatment of PCP-R cells with an NKCC and KCC inhibitor cocktail prior to 
addition of a TRPV4 agonist. Net changes in transepithelial ion flux and conductance were 
measured. A bumetanide (100 µM) and R-(+)-DIOA (25 µM) cocktail was added both apically 
and basolaterally at T = -10 minutes. The TRPV4 agonist GSK1016790A was added to the 
basolateral side of the membrane in all cultures at T = 0 minutes. Pre-incubation with the 
bumetanide and R-(+)-DIOA cocktail is represented by white open circles. The GSK-treated 
positive controls are denoted by black filled circles. Circles represent mean values, and error 
bars represent +/- SEM for the n indicated. SCC = short circuit current. * = p < 0.05 against 
control experiments. 
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Figure 3.7 Effect of NKCC and KCC Inhibitors on TRPV4-Mediated Responses.  
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Figure 3.8: Relative fold change of mRNAs in PCP-R cells 24 hours post-incubation with a 
specific inhibitor of NKCC. Bumetanide (100 µM) was added both apically and basolaterally 
to individual experimental wells (n=6 for each inhibitor). The fold change in TRPV4, NKCC 
or SPAK in bumetanide-treated cultures are shown relative to normalized controls (n=6). 
GAPDH and RPS18 were used as housekeeping genes to calculate the 2- ∆∆CT fold change in 
each gene. Individual points shown are the minimum and maximum fold change values. Boxes 
represent +/- SEM for the experiments indicated, and the line within each box represents the 
mean value for those experiments. 
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Figure 3.8 Effect of NKCC Inhibitor on mRNA Transcription. 
Relative fold change of mRNAs in PCP-R cells 24 hours post-incubation with a specific inhibitor 
of NKCC. Bumetanide (100 µM) was added both apically and basolaterally to individual 
experimental wells (n=6 for each inhibitor). The fold change in TRPV4, NKCC or SPAK in 
bumetanide-treated cultures are shown relative to normalized controls (n=6). GAPDH and RPS18 
were used as housekeeping genes to calculate the 2- ∆∆CT fold change in each gene. Individual 
points shown are the minimum and maximum fold change values. Boxes represent +/- SEM for 
the experiments indicated, and the line within each box represents the mean value for those 
experiments. 
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Figure 3.9: Relative fold change of mRNAs in PCP-R cells 24 hours post-incubation with a 
specific inhibitor of SPAK. STOCK2S 26016 (1 µM) was added both apically and basolaterally 
to individual experimental wells (n=6 for each inhibitor). The fold change in TRPV4, NKCC 
or SPAK are shown relative to normalized controls (n=6). GAPDH and RPS18 were used as 
housekeeping genes to calculate the 2-∆∆CT fold change in each gene. Individual points shown 
are the minimum and maximum fold change values. Boxes represent +/- SEM for the 
experiments indicated, and the line within each box represents the mean value for those 
experiments. 
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Figure 3.9 Effect of SPAK Inhibitor on mRNA Transcription. 
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 CHLORIDE CHANNELS IN CPE TRANSEPITHELIAL 
TRANSPORT 
4.1 Introduction 
Transcellular transport of ions forms the basis of CSF production, and several chloride channels 
have been described for their roles in Cl- movement across the choroid plexus (CP) epithelium (1-
5,8-13,20,22,25,27,33,34,36,39). Perhaps the best described transporter of Cl- in the CP is the Na-
K-2Cl cotransporter (NKCC). First described in the kidney, and encoded by the SLC12A genes, 
NKCC couples the movement of sodium and potassium to the movement of 2 chloride ions, in 
unidirectional fashion (4,5,10-13,17,22,36). In the CP, NKCC1 (SLC12A2) has been shown to be 
reversible, such that the direction of movement can be either net influx, or net efflux, depending 
on the intracellular [Cl-] (12,16). In addition to NKCC, the potassium chloride cotransporters 
(KCC1-4) have also been shown to transport Cl- in the CP (4,5,10,11,21). The KCCs have been 
described on both the apical and basolateral membranes of the CP, and operate in the net efflux 
direction, driving Cl- and potassium out of the cell to either the blood or luminal surfaces. The 
roles of NKCC and the KCCs in transepithelial transport are described more fully in chapter 3. 
 
Anion exchange protein 2 (AE2, SLC4A2) and the sodium-driven chloride bicarbonate exchanger 
(NCBE, NBCn2, SLC4A10) are both chloride-bicarbonate exchangers in the CP, and both have 
been described exclusively on the basolateral membrane of the epithelium (2-
5,8,10,11,19,25,33,34,36,37). AE2 is thought to be the primary basolateral loader of Cl- in to the 
CP, which is then passed through the apical membrane by Cl- extruders (2,4,5). In other tissues 
such as renal tubules and epithelia of the gastrointestinal tract, AE2 is similarly expressed on the 
basolateral surface and plays a key role in basal loading of Cl- ions in to transporting epithelia 
(2,11). AE2 operates at the basal surface by exchanging extracellular Cl- for intracellular HCO3- 
(2,10,11). In contrast to AE2, NCBE is the primary basal loader of HCO3- in the CP (3,10,11). 
NCBE works in an opposite manner to AE2, extruding Cl- in exchange for extracellular HCO3- 
and Na+. These channels are important for two distinct cellular processes. AE2, as previously 
mentioned, loads Cl- in the extracellular space, to be secreted at the apical surface into the 
intraventricular space. NCBE operates primarily in maintenance of intracellular pH, by increasing 
intracellular HCO3- and acidifying the cytoplasm (11). NCBE also contributes to epithelial 
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transport of ions, albeit in a manner opposite to AE2, allowing for transepithelial transport of 
HCO3- to be extruded on the apical surface by the sodium bicarbonate cotransporter (NBCe2, 
SLC4A5), an electroneutral transporter of HCO3- and Na+ (7,11,34). Interestingly, both AE2 and 
NCBE have been described as being DIDS sensitive, an important consideration for their 
apparently opposite roles in Cl-/HCO3- exchange (1,3). 
 
Several channels exist on the apical surface of CP cells which are capable of extruding Cl- loaded 
by AE2 on the basolateral surface. Previously, a channel known as the voltage regulated anion 
channel (VRAC) was shown to be a minor contributor to Cl- movement across the apical surface 
(11). Recently, VRAC was identified as the leucine-rich repeat-containing protein 8 (LRRC8) 
(13,15,26,38,40,42). VRAC is a key player in the maintenance of cell volume regulation and 
responds to intracellular swelling by driving water and K+ efflux to reduce intracellular volumes 
(13,15,38). VRAC appears to be ubiquitously expressed in mammalian cells, contributing to 
regulatory volume decrease (RVD) across all cell types (10,13). 
 
CFTR has been identified as the primary protein dysregulated in cystic fibrosis. More than 2000 
mutations have been described in the CFTR gene, more than 200 of which results in a cystic 
fibrosis phenotype, with a deletion at phenylalanine 508, ΔF508 being the most common 
contributor to cystic fibrosis (6). Localized to the apical surface in all cell types in which it is 
expressed, CFTR is regulated by cyclic AMP (cAMP)-dependent protein kinase A (PKA) 
phosphorylation (6,18,23). Conflicting reports question the presence of CFTR in the CP, and some 
controversy exists regarding its expression. In 1995, Hincke et al showed by western blot and 
immunolocalization studies that CFTR was found in rat CP (18). However, in 1996 and 1997, 
several studies demonstrated that CFTR mRNA was not present in rat CP by RT-PCR and in-situ 
hybridization studies (10,23,24). Current opinions are that CFTR is likely not expressed in most 
mammalian CP and is not likely involved in transepithelial transport of Cl- (10,23).  
 
Ca2+-activated Cl- channels (CaCC’s) are channels which respond to increases in intracellular 
[Ca2+] by extruding Cl- (6,31,32,39,41). CaCC’s are comprised primarily of the anoctamin family 
of channels, which includes the transmembrane member 16 (TMEM16A-K) genes (6,18,32).  
TMEM16A is a Ca2+-activated Cl- channel that was initially identified in 2008 (41). TMEM16A 
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is thought to be localized to the apical membrane and acts as a Cl- extruder (39). In airway and 
intestinal epithelium, TMEM16A is thought to contribute a minor part to Cl- conductance (28). In 
mandibular acinar cells, TMEM16A was immunolocalized to the apical membrane, demonstrating 
that CaCC’s exist on the apical surface as Cl- extruders (31). Largely ignored in the CP, one study 
demonstrated that TMEM16A was natively expressed in the CP of mice and contributed to Cl- 
efflux from the epithelium (38). 
 
The role of TRPV4 in Cl- transport has not been well studied. As a non-selective Ca2+ permeable 
cation channel, TRPV4 is capable of increasing intracellular [Ca2+] (27,29,35). This increase in 
[Ca2+] may activate CaCC’s, and stimulate the transport of Cl- in the CP. Additionally, TRPV4 has 
been shown to be regulated by WNK4 activity, which responds to increases in intracellular [Cl-] 
(14). This suggests that TRPV4 may be involved in evoking and integrating various molecular 
signals responsible for efflux of Cl- in the CP (39). Here we describe the interaction between 
TRPV4 and TMEM16A, responsible for mediating transepithelial ion flux at the CP. These 
interactions appear not to be mediated by activity of basal Cl- loaders AE2 and NCBE, CFTR, or 
VRAC.  
4.2 Methods and Materials 
Cell Culture: PCP-R cells were seeded on 6-well cluster plates containing 0.4 µM filter diameter 
polycarbonate permeable bottom supports (Corning Life Sciences, Lowell, MA; #3412) for 
approximately 10-12 days, until cell cultures achieved a transepithelial resistance (TER) >500 
Ωcm2. Cultures below 500 Ωcm2 were not considered high resistance and were not used for 
experiments. Additionally, cultures whose TERs dropped below 100 Ωcm2 during the time course 
of the experiments were also not used, due to irreversible changes in the tight junctions. PCP-R 
cell cultures were grown using DMEM (Gibco, Gaithersburg, MD; #12100-046), with 4.5 g/L 
glucose, 3.7 g/L NaHCO3, 24 mM HEPES, 10% fetal bovine serum (Atlanta Biologicals, Flowery 
Branch, GA), 100 U/ml penicillin, 100 mg/ml streptomycin, and 5 µg/ml insulin. Cells were bathed 
in 2 ml of the PCP-R media apically (filter top) and 3 ml basolaterally (filter bottom). PCP-R 
media was replaced 3 times weekly. 
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Electrophysiology: For electrophysiological analysis, PCP-R cells were grown on transwell plates 
until confluent (10-12 days), excised and subsequently mounted in Ussing chambers connected to 
a DVC-1000 Voltage/Current clamp (World Precision Instruments, Sarasota, FL) with voltage and 
current electrodes attached on either side of the membrane. Each side of the chamber was bathed 
in 10 ml of serum free media at 37°C. Media-containing chambers were water jacketed to maintain 
a constant physiological temperature of 37°C. A 5% CO2/95% O2 gas lift circulated media through 
chambers and oxygenated the chamber-mounted cells. The spontaneous transepithelial potential 
difference was clamped to zero, and cells were allowed to equilibrate for at least 20 minutes. 
Experimental compounds were added to the apical and/or basal media, and the resulting short 
circuit current (SCC) was recorded as a measurement of net transepithelial ion movement. By 
convention, a positive deflection of the SCC represents either anion secretion (blood to CSF 
directed movement) or cation absorption (CSF to blood), while the opposite is true for a negative 
deflection. Additionally, a 2 mV pulse was applied every 180 seconds, and the resulting change in 
SCC was recorded. This change in SCC was used to calculate transepithelial resistance (TER) 
using Ohm’s Law, and the resulting TER values were converted to transepithelial conductance by 
calculating the inverse of the TER. The transepithelial conductance is an indication of net ion 
movement and barrier permeability in cells. A low conductance (<2 mS/cm2) represents low net 
ion movement and a tight barrier. Any increase in the transepithelial conductance is observed to 
be an increase in the transepithelial ion movement and/or increased cellular permeability. For all 
electrophysiological experiments, both the control and experimental groups were analyzed 
simultaneously, as represented in the graphs. 
 
Reverse Transcriptase (RT)-PCR: PCP-R cells were grown to confluence on transwells. Cell 
monolayers were washed twice with cold 1X PBS, and total cell RNA was isolated utilizing the 
Monarch Total RNA Miniprep Kit (New England Biolabs, #T2010S) according to the 
manufacturer’s directions for cultured mammalian cells. RNA concentration was measured using 
an ND2000 Nanodrop (Fisher Scientific, Waltham, MA). Approximately 100 ng of total RNA was 
reverse transcribed into cDNA using the Monarch LunaScript RT SuperMix Kit (New England 
Biolabs; #E3010L), along with corresponding No-template and -RT controls, according to the 
manufacturer’s directions. Sus Scrofa exon mRNA sequences for each gene were obtained using 
Ensembl, and primer pairs for each were designed using Primer3Plus. Approximately 500 ng of 
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template cDNA was combined with the forward and reverse primers (IDT, Coralville, IA), as well 
as GoTaq Green Master Mix (Promega Corporation, Madison, WI; #M7122). Reactions were run 
as a gradient to determine optimum annealing temperature for each primer pair, and products were 
separated on a 1.5% agarose gel with ethidium bromide. Flanking 100 bp ladders were used as 
molecular weight markers, and gels were imaged using a ChemiDoc XRS imager (Bio-Rad, 
Hercules, CA). Single band amplicons of the predicted molecular weight were sequenced (Eton 
Biosciences, Union, NJ) and the correct products were validated using NCBI and Ensembl BLAST. 
 
Statistics: Statistics were calculated using Two-tailed Students t-test in Sigma Plot 13. p < 0.05 is 
considered significant. Student’s t-test was used to compare experimental groups to the control as 
indicated by the symbols defined in the figure legends. 
 
4.3 Results 
We used three sets of redundant primer pairs for each gene of interest to determine its presence in 
the PCP-R cells and sequenced the resulting single band amplicons to confirm correct gene 
amplification (Table 1). mRNA encoding for TMEM16A and CFTR, both Ca2+-activated Cl- 
channels was identified (Figure 1). The presence of CFTR mRNA is somewhat surprising, given 
the body of literature suggesting CFTR is absent in other mammalian cells. 
 
We used Ussing chamber electrophysiology to record net electrogenic changes in transepithelial 
ion flux and barrier permeability. By convention, a negative change in SCC is representative of 
net transepithelial ion transport consistent with anion absorption (CSF to blood) or cation secretion 
(blood to CSF). An increase in conductance is consistent with an increase in barrier permeability 
of the cells. For each figure, experiments were conducted with paired controls which utilize an 
agonist of either TMEM16A or TRPV4. In each experiment, the control agonist was added at time 
T = 0. In experimental cultures, cells were pretreated with specific inhibitors, modulators or 
agonists 10 minutes prior to or following the addition of the control agonist.  
 
Pre-treatment of PCP-R cell cultures with 10 µM T16Ainh-A01, a specific inhibitor of TMEM16A 
on both the apical and basolateral membranes 10 minutes prior to the addition of the TMEM16A 
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agonist 1.5 µM EACT resulted in a statistically significant inhibition of TMEM16A-mediated ion 
flux and conductance changes (Figure 2). This stimulator/inhibitor pairing substantiates the 
specificity of the response for TMEM16A. 
 
To investigate whether TMEM16A plays a role in TRPV4-mediated ion flux, PCP-R cells were 
pretreated with 10 µM T16Ainh-A01 on both the apical and basolateral membranes 10 minutes 
prior to addition of the TRPV4 agonist GSK1016790A (3 nM) on the basolateral membrane. 
Pretreatment with T16Ainh-A01 resulted in inhibition of TRPV4-stimulated ion flux, as well as 
an inhibition of the TRPV4-stimulated conductance chances (Figure 3). To determine if this effect 
was restricted to one side of the membrane, cultures were treated on either the apical or basolateral 
sides with 10 µM T16Ainh-A01 prior to the addition of 3 nM GSK1016790A. Inhibition of 
TMEM16A on the apical surface resulted in greater inhibition of the TRPV4-mediated SCC 
responses than did inhibition of TMEM16A on the basal surface. However, both were found to 
result in statistically significant inhibition of the TRPV4 response. Interestingly, pretreatment on 
either membrane resulted in complete inhibition of the conductance increases observed upon 
TRPV4 activation (Figure 4). 
 
To determine if the TRPV4-induced SCC and conductance changes could be reversed, we first 
treated cells with 3 nM GSK1016790A for 10 minutes followed by treatment with 10 µM 
T16Ainh-A01. Inhibition of TMEM16A following activation of TRPV4 resulted in a reversal of 
the TRPV4-induced SCC changes, while the increase in conductance was only shown to plateau 
rather than reverse (Figure 5). 
 
Next we attempted to determine if TRPV4 and TMEM16A were co-dependent for activation. 
Previously we had determined that inhibition of TMEM16A was capable of inhibiting the TRPV4 
response (Figures 3,4,5). To determine the reciprocal nature, we pretreated cells with 50 µM 
RN1734, a specific TRPV4 inhibitor, prior to addition of the TMEM16A agonist EACT (1.5 µM). 
Similar to inhibition of the TRPV4 response via inhibition of TMEM16A, we observed that the 
TMEM16A-induced SCC and conductance changes were blocked by inhibiting TRPV4 (Figure 
6).  
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To further elucidate the complex interactions between TMEM16A and TRPV4, we pretreated cells 
with low dose (300 pM) GSK1016790A, followed by low dose EACT (1.5 µM). Independently, 
GSK1016790A and EACT were not capable of stimulating SCC or conductance changes. However, 
when cells initially treated with GSK were followed with low dose EACT, a small decrease in 
SCC was observed, with no changes in conductance being noted (Figure 7). To determine whether 
TMEM16A played a role in the multiphasic SCC response induced by TRPV4 activation, we 
initially treated PCP-R cells with 1.5 µM EACT. These cells were then treated with 300 pM 
GSK1016790A. Interestingly, following activation of TMEM16A, a monophasic SCC response 
was observed upon activation of TRPV4. It was also observed that upon addition of 
GSK1016790A, only a moderate increase in conductance was observed (Figure 8). 
 
We next investigated whether other apical Cl- channels played a role in the TRPV4 pathway. To 
determine the role of CFTR, cells were pretreated with the specific inhibitor CFTRinh172 (50 µM) 
both apically and basolaterally, followed by 3 nM GSK1016790A. No significant effects on SCC 
or conductance were observed in response to CFTR inhibition (Figure 9). Similarly, apical and 
basal pretreatment with a VRAC inhibitor, DCPIB (1 µM) resulted in no significant effects on the 
TRPV4-stimulated responses. 
  
Finally, to determine the role of basolateral Cl-/HCO3- exchangers in the TRPV4 mechanism, cells 
were pretreated with 10 µM DIDS, an inhibitor of both AE2 and NCBE prior to addition of 3 nM 
GSK1016790A. No effects on the TRPV4-mediated SCC and conductance changes were observed 
when pretreated with DIDS relative to the GSK controls (Figure 10). 
 
4.4 Discussion 
Chloride is thought to be the major anion regulated for cell volume regulation and homeostasis in 
most mammalian cell types (10,11,33). To accomplish this, several well described Cl- channels 
and transporters maintain exquisite control over intracellular [Cl-], adjusting intracellular 
concentrations to match physiological needs (4,5,10,11,27,33). In the choroid plexus, CSF is 
produced by transepithelial movement of ions and other small molecules from the serum to the 
intraventricular space which drives movement of water (11,33). Paramount to this is the movement 
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of Cl-, which is introduced to the cytoplasm primarily by basal Cl-/HCO3- exchangers such as AE2 
(1,2,10). From there, Cl- is extruded from the cell via apically bound transporters (4,5,10). A 
gradient of [Cl-] exists across the CP, with plasma [Cl-] reported at approximately 106 mM, and 
CSF [Cl-] at 130 mM, requiring specific transporters to move Cl- against a transepithelial chemical 
gradient (10). 
 
Previous reports have described the roles of NKCC1 and KCC4 in apical Cl- transport out of CP 
cells (4,5,10,11). In addition to transepithelial movement, several channels and transporters exist 
with the primary role of maintaining intracellular pH and homeostasis by way of exchanging 
extracellular HCO3- in the blood for cytoplasmic Cl-, thus acidifying the cytoplasm. In the CP, 
NCBE appears to be the primary basolateral transporter responsible for this exchange (11). On the 
apical surface, NKCC1 also plays a role in cell homeostasis (11,12,16). This transporter appears 
to be reversible, such that the direction of flow can operate in net influx to transport Cl-, Na+ and 
K+ back into the cell, depending primarily on the intracellular [Cl-]. KCC3 and KCC4 are K+/Cl- 
cotransporters located on the basal and apical surfaces, respectively (4,5,10,20). These transporters 
appear to primarily be responsible for extrusion of Cl- on either surface in maintenance of the [Cl-] 
gradient across the CP (4,5,10). 
 
A body of literature exists describing the role of NKCC1 in CP-dependent CSF production and 
transepithelial transport (4,5,10,12,16). In chapter 3, we describe the role of NKCC1 in the PCP-
R cells and demonstrated that NKCC1 appears to play a minor role in TRPV4-mediated 
electrogenic ion flux across the CP. However, other Cl- channels responsible for secretion have 
not been well described in the CP, nor their roles in CSF production elucidated. TMEM16A, a 
Ca2+-activated Cl- channel is one such protein. Increases in intracellular Ca2+ stimulate the 
excitation of TMEM16A, causing secretion of Cl- in to the lumen (32). Activation of TRPV4 
results in increases in intracellular Ca2+ and may be capable of activating TMEM16A. 
 
To characterize the Cl- channels and transporters in the CP, we first performed RT-PCR identifying 
mRNAs encoding for TMEM16A and CFTR. CFTR, a key Cl- extruder in other epithelia such as 
lung and kidney, appears not to be present in the CP according to several reports (10,23,24). 
(10,23,24). The expression of CFTR in the PCP-R cells is therefore a somewhat curious finding. 
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In chapter 3, we identified the mRNAs encoding for NKCC1, as well as KCC3 and KCC4, both 
of which have been previously described in the CP. These results are consistent with previous 
reports showing expression of a variety of Cl- channels, transporters and exchangers in the CP 
(4,5,10). 
 
The role of CaCC’s in CSF production remains elusive. In airway and intestinal epithelia, 
TMEM16A was shown to contribute to CaCC-dependent currents (28). Interestingly, in the same 
study TMEM16A was also shown in salivary gland epithelia to be responsible for nearly all of the 
CaCC-dependent current. Conversely, little is known about TMEM16A and its expression in the 
CP or any role it may play in CSF production. 1.5 µM EACT, an activator of TMEM16A evoked 
an initial decrease in SCC consistent with either anion absorption or cation secretion, followed by 
an increase in SCC, indicative of the reverse. This change in SCC was mitigated by pretreatment 
with 10 µM T16AinhA01, a TMEM16A-specific inhibitor.  
 
Previously, it has been demonstrated that TRPV4 activation with GSK1016790A (3 nM) results 
in a multiphasic transepithelial ion flux response along with an acute increase in conductance (35). 
Pretreatment with the TMEM16A inhibitor substantially blocked this TRPV4-mediated SCC and 
conductance change, suggesting a functional interaction between the two channels.  Addition of 
the TMEM16A inhibitor to either the apical or serosal media resulted in significant inhibition of 
the resulting SCC changes elicited by TRPV4 activation, although this effect was more 
pronounced on the apical surface. Interestingly, addition of the inhibitor to either side had the same 
inhibitory effect on the conductance changes, substantially blocking any TRPV4-mediated 
increases in SCC. Somewhat unexpectedly, the conductance increase observed upon activation of 
TMEM16A is smaller than the conductance changes observed upon activation of TRPV4, 
suggesting that TRPV4 plays a larger role in maintenance of cell permeability. 
 
In chapter 2, we showed that the TRPV4-mediated SCC and conductance changes could be 
reversed and returned to baseline upon addition of the TRPV4 inhibitor RN1734. Addition of the 
TMEM16A inhibitor to TRPV4 agonist treated cultures had a similar effect on the SCC changes; 
upon addition of the TMEM16A inhibitor, the initial SCC decrease acutely returned to baseline. 
However, unlike the previous studies, the TMEM16A inhibitor was not able to reverse the 
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conductance increase, instead resulting in plateauing of the conductance. To further explore the 
relationship, cells were pretreated with the TRPV4 inhibitor RN1734 (50 µM), followed by the 
TMEM16A activator EACT (1.5 µM). Here, inhibition of TRPV4 was able to completely block 
both the SCC and conductance changes caused by TMEM16A activation. These data suggest a 
complicated interaction between TMEM16A and TRPV4 by which the channels are reciprocally 
dependent upon each other for activation; inhibition of either blocks channel activation of the other. 
 
In the PCP-R cells, TRPV4-mediated changes in the SCC are not observable when treated with 
GSK1016790A below 1 µM (35). Therefore, to further interrogate the complex interactions 
between TMEM16A and TRPV4, cells were treated initially with the TRPV4 agonist at a sub 
micromolar concentration (300 pM), followed by a concentration of the TMEM16A agonist (150 
nM) which also does not elicit a SCC response. The combined effect of low-dose stimulation of 
both TRPV4 and TMEM16A resulted in a small but measurable decrease in SCC, while resulting 
in no net conductance changes. When stimulated with 1.5 µM EACT, followed by 300 pM 
GSK1016790A, a complex SCC response was observed. An initial acute decrease in SCC, 
followed by a return to baseline was observed, typical of TMEM16A activation. However, upon 
addition of GSK1016790A at 300 pM, a biphasic SCC response was observed, instead of the 
typical multiphasic SCC response observed upon activation of TRPV4 with 3 nM GSK1016790A. 
These data together further suggest a complex interaction between TMEM16A and TRPV4 in 
which each channel responds to the other’s activation.  
 
While mRNA encoding CFTR was identified in the PCP-R cells, it is not believed to play a role 
in transepithelial flux of ions in the CP. When pretreated with CFTRinh172, no inhibition of 
GSK1016790A-induced electrogenic ion flux or conductance was observed. These data therefore 
suggest that CFTR is not responsible for anion currents in the CP. 
 
The voltage regulated anion channel VRAC thought to be a significant contributor to Cl- currents 
in the CP was recently identified as LRRC8 (13,15,25,38,40). This channel is thought to play a 
role in cell volume regulation, primarily through regulatory volume decrease (13,15,26,38,40,42). 
To investigate whether VRAC contributes to TRPV4-stimulated electrogenic ion flux, cells were 
pretreated with 1 µM DCPIB, a specific inhibitor of VRAC. Inhibition of VRAC did not alter the 
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TRPV4-induced changes in SCC or conductance, suggesting that VRAC is not involved in 
TRPV4-mediated ion flux.  
 
Transepithelial ion flux is dependent on activity of channels on both the apical and basolateral 
surfaces of the CP (9,10,32,34). On the basolateral membrane, the DIDS-sensitive Cl-/HCO3- 
exchanger AE2 is believed to be the primary loader of Cl- in to the cytoplasm from the serum, 
secreting HCO3- in to the plasma in exchange for extracellular Cl- (2,4,5,25,33,37). Operating in 
reverse to AE2, NCBE is a DIDS-sensitive Cl-/HCO3- exchanger that has the added benefit of 
absorbing plasma Na+ into the cell along with HCO3- (3,10). To determine whether either of these 
exchangers are involved in TRPV4-mediated ion flux at the basolateral surface, cells were treated 
with 10 µM DIDS, followed by 3 nM GSK1016790A. No effect on either the SCC or the 
transepithelial conductance was observed, suggesting that AE2 and NCBE are not likely involved 
in the TRPV4 pathway of ion flux. 
 
In summary, we have demonstrated that TMEM16A activation is dependent on TRPV4 activity. 
In addition, TRPV4 activation is also dependent on TMEM16A activity, suggesting a reciprocal 
interaction. Stimulation of either channel was blocked by inhibition of the other, and it was shown 
that TRPV4-induced currents were reversible upon inhibition of TMEM16A. Our studies further 
demonstrated that while many canonical CP Cl- transporters are present in the PCP-R cell line, 
only TMEM16A appears to be significantly involved in the TRPV4 pathway of transepithelial ion 
flux. CFTR appears not to play a significant role in TRPV4-evoked electrogenic ion flux, nor does 
VRAC. Additionally, we demonstrated that inhibition of basal Cl- transport did not have a 
significant effect on TRPV4-mediated transport. These data suggest a complex interaction between 
TMEM16A and TRPV4 which deserves further investigation. If in fact TRPV4 acts a hub protein 
to integrate complex molecular signals to stimulate CSF production, TMEM16A may be an 
intriguing point of regulation worthy of additional studies. 
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Table 4.1 Sus Scrofa Primers Used for RT-PCR with Corresponding Product Sizes (bp).  
Three different primer sets were generated and tested for each gene. Primers included in this table 
were utilized for Figure 1. GAPDH was used as a positive control. 
Sus 
Scrofa 
gene 
Protein Primer Sequences 5' - 3' Product 
Size (bp) Forward Primer Reverse Primer 
Ano1 TMEM16A CTCACCAAGATCGAGGTTCCAA GGGGTGTAGGAATTCACGAACT 95 
CFTR CFTR AAAGCATTCACCGAAAGACAG
C 
GGTTGACATAGGGGCTTGAAGA 548 
Gapdh GAPDH TTTTAACTCTGGCAAAGTGGAC CATTGTCGTACCAGGAAATGAG 884 
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Figure 4.1 RT-PCR in the PCP-R Cell Line. 
mRNA for TRPV4, TMEM16A, and CFTR are present in the PCP-R cell line. GAPDH was used 
as a positive control. 100 bp flanking ladders were used. RT = Reverse transcriptase. Lanes 
denoted as (+) or (-) RT identify the presence or absence of reverse transcriptase in the PCR 
mixture. 
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Figure 4.2: Pre-treatment of PCP-R cells with a TMEM16A inhibitor prior to addition of a 
TMEM16A agonist. Net changes in transepithelial ion flux and conductance were measured. 
T16Ainh-A01 (10 µM) was added to both the apical and basolateral surfaces at T = -10 
minutes. The TMEM16A agonist EACT (1.5 µM) was added to both the apical and basolateral 
sides of the membrane in all cultures at T = 0 minutes. Pre-incubation with T16Ainh-A01 is 
represented by white open circles. The EACT-treated positive controls are denoted by black 
filled circles. Circles represent mean values, and error bars represent +/- SEM for the n 
indicated. SCC = short circuit current. * = p < 0.05 against control experiments. 
 
 
124 
T16Ainh-A01  Pretreatment SCC
Time (min)
-20 -10 0 10 20 30
SC
C
 ( 
A/
cm
2 )
-6
-4
-2
0
2
4
EACT control n=6
T16AinhA01 Pretreatment n=6
T16Ainh-A01 (10 µM)


EACT (1.5 uM)
*
*
**
 
T16Ainh-A01  Pretreatment Conductance
Time (min)
-20 -10 0 10 20 30
C
on
du
ct
an
ce
 (m
S/
cm
2 )
0
2
4
6
EACT control n=6
T16AinhA01 Pretreatment n=6
T16Ainh-A01 (10 µM)


EACT (1.5 uM)
 
Figure 4.2 Effect of TMEM16A Inhibitor on TMEM16A-Mediated Responses.  
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Figure 4.3: Pre-treatment of PCP-R cells with a TMEM16A inhibitor prior to addition of a 
TRPV4 agonist. Net changes in transepithelial ion flux and conductance were measured. 
T16Ainh-A01 (10 µM) was added to both the apical and basolateral surfaces at T = -10 
minutes. The TRPV4 agonist GSK1016790A (3 nM) was added to both the apical and 
basolateral sides of the membrane in all cultures at T = 0 minutes. Pre-incubation with 
T16Ainh-A01 is represented by white open circles. GSK-treated positive controls are denoted 
by black filled circles. Circles represent mean values, and error bars represent +/- SEM for the 
n indicated. SCC = short circuit current. * = p < 0.05 against control experiments. 
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Figure 4.3 Effect of TMEM16A Inhibitor on TRPV4-Mediated Responses.  
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Figure 4.4: Sidedness of a TMEM16A inhibitor prior to addition of a TRPV4 agonist. Net 
changes in transepithelial ion flux and conductance were measured. T16AinhA01 (10 µM) was 
added either apically or basolaterally at T = -10 minutes. The TRPV4 agonist GSK1016790A 
(3 nM) was added to the basolateral side of the membrane in all cultures at T = 0 minutes. Pre-
incubation with T16Ainh-A01 either apically, or basolaterally is represented by white open 
circles or grey filled triangles, respectively. The GSK-treated positive controls are denoted by 
black filled circles. Circles represent mean values, and error bars represent +/- SEM for the n 
indicated. SCC = short circuit current. * = p < 0.05 against control experiments. 
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Figure 4.4 Sidedness of TMEM16A Inhibitor on TRPV4-Mediated Responses.  
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Figure 4.5: Reversibility of a TRPV4 agonist response by a TMEM16A antagonist.  Net 
changes in transepithelial ion flux and conductance were measured. The TRPV4 agonist 
GSK1016790A (3 nM) was added to the basolateral surface of all cultures at T = 0 minutes.  
T16Ainh-A01 (10 µM) was added both apically and basolaterally at T = 10 minutes. Post-
treatment with T16Ainh-A01 is represented by white open circles. The GSK-treated positive 
controls are denoted by black filled circles. Circles represent mean values, and error bars 
represent +/- SEM for the n indicated. SCC = short circuit current. * = p < 0.05 against control 
experiments. 
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Figure 4.5 Reversibility of a TRPV4 Agonist Response by a TMEM16A Inhibitor.  
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Figure 4.6: Pre-treatment of PCP-R cells with a TRPV4 inhibitor prior to addition of a 
TMEM16A agonist. Net changes in transepithelial ion flux and conductance were measured. 
RN1734 (50 µM) was added to both the apical and basolateral surfaces at T = -10 minutes. The 
TMEM16A agonist EACT (1.5 µM) was added to both the apical and basolateral sides of the 
membrane in all cultures at T = 0 minutes. Pre-incubation with RN1734 is represented by white 
open circles. The EACT-treated positive controls are denoted by black filled circles. Circles 
represent mean values, and error bars represent +/- SEM for the n indicated. SCC = short circuit 
current. * = p < 0.05 against control experiments. 
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Figure 4.6 Effect of TRPV4 Inhibitor on TMEM16A-Mediated Responses. 
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Figure 4.7: Pre-treatment of PCP-R cells with a TRPV4 agonist prior to addition of a 
TMEM16A agonist. Net changes in transepithelial ion flux and conductance were measured. 
GSK1016790A (300 pM) was added to the basolateral surfaces of experimental and TRPV4 
control cultures at T = -10 minutes. The TMEM16A agonist EACT (1.5 µM) was added to 
both the apical and basolateral sides of the membrane in experimental cultures and TMEM16A 
control cultures at T = 0 minutes. Pre-incubation with GSK1016790A prior to addition of 
EACT is represented by white open circles. The GSK-treated controls are denoted by black 
filled circles. The EACT controls are denoted by grey filled triangles. Circles represent mean 
values, and error bars represent +/- SEM for the n indicated. SCC = short circuit current. * = p 
< 0.05 against control experiments. 
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Figure 4.7 Effect of Low Dose Agonists on TMEM16A and TRPV4 Induced Responses. 
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Figure 4.8: Pre-treatment of PCP-R cells with a TMEM16A agonist prior to addition of a 
TRPV4 agonist. Net changes in transepithelial ion flux and conductance were measured. EACT 
(10 µM) was added to both the apical and basolateral surfaces at T = -10 minutes. The TRPV4 
agonist GSK1016790A (300 pM) was added to both the apical and basolateral sides of the 
membrane in all cultures at T = 0 minutes. Pre-incubation with EACT is represented by white 
open circles. The GSK-treated controls are denoted by black filled circles. Circles represent 
mean values, and error bars represent +/- SEM for the n indicated. SCC = short circuit current. 
* = p < 0.05 against control experiments. 
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Figure 4.8 Effect of TMEM16A and TRPV4 Agonist on TMEM16A and TRV4 Responses. 
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Figure 4.9: Pre-treatment of PCP-R cells with a CFTR inhibitor prior to addition of a TRPV4 
agonist. Net changes in transepithelial ion flux and conductance were measured. CFTRinh172 
(50 µM) was added to both the apical and basolateral surfaces at T = -10 minutes. The TRPV4 
agonist GSK1016790A (3 nM) was added to both the apical and basolateral sides of the 
membrane in all cultures at T = 0 minutes. Pre-incubation with CFTRinh172 is represented by 
white open circles. The GSK controls are denoted by black filled circles. Circles represent 
mean values, and error bars represent +/- SEM for the n indicated. SCC = short circuit current. 
* = p < 0.05 against control experiments. 
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Figure 4.9 Effect of CFTR Inhibitor on TRPV4-Mediated Responses. 
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Figure 4.10: Pre-treatment of PCP-R cells with a VRAC inhibitor prior to addition of a TRPV4 
agonist. Net changes in transepithelial ion flux and conductance were measured. DCPIB (1 
µM) was added to both the apical and basolateral surfaces at T = -10 minutes. The TRPV4 
agonist GSK1016790A (3 nM) was added to both the apical and basolateral sides of the 
membrane in all cultures at T = 0 minutes. Pre-incubation with DCPIB is represented by white 
open circles. The GSK controls are denoted by black filled circles. Circles represent mean 
values, and error bars represent +/- SEM for the n indicated. SCC = short circuit current. * = p 
< 0.05 against control experiments. 
 
 
140 
DCPIB Pretreatment SCC
Time (min)
-20 -10 0 10 20 30
SC
C
 ( 
A/
cm
2 )
-6
-4
-2
0
2
GSK1016790A n=3
DCPIB Pretreatment n=3

GSK1016790A (3 nM)

DCPIB(1 M)
*
 
DCPIB Pretreatment Conductance
Time (min)
-20 -10 0 10 20 30
C
on
du
ct
an
ce
 (m
S/
cm
2 )
1
2
3
4
5
6
GSK1016790A n=3
DCPIB Pretreatment n=3
GSK1016790A (3 nM)

DCPIB(1 M)
 
Figure 4.10 Effect of VRAC Inhibitor on TRPV4-Mediated Responses.  
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Figure 4.11: Pre-treatment of PCP-R cells with a Cl-/HCO3- exchange inhibitor prior to addition 
of a TRPV4 agonist. Net changes in transepithelial ion flux and conductance were measured. 
DIDS (10 µM) was added to both the apical and basolateral surfaces at T = -10 minutes. The 
TRPV4 agonist GSK1016790A (3 nM) was added to both the apical and basolateral sides of 
the membrane in all cultures at T = 0 minutes. Pre-incubation with DIDS is represented by 
white open circles. The GSK controls are denoted by black filled circles. Circles represent 
mean values, and error bars represent +/- SEM for the n indicated. SCC = short circuit current. 
* = p < 0.05 against control experiments. 
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Figure 4.11 Effect of Anion Exchange Inhibitor on TRPV4-Mediated Responses. 
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 INFLAMMATORY EFFECTS ON TRPV4 IN THE 
CHOROID PLEXUS 
5.1 Preface 
This publication was accepted by the American Journal of Physiology: Cell Physiology in August 
2019. For this article, I was the second author. My contributions to this publication included 
conducting RT-PCR experiments to look at the expression of mRNAs for several cytokine 
receptors, as well as preparation of figures associated with the RT-PCR experiments (Figure 1). 
Additionally, I designed qPCR experiments to look at the expression of TRPV4 mRNA in cells 
treated with various cytokines. These experiments demonstrated that overnight incubation with the 
cytokines had no significant effect on the expression of TRPV4 mRNA in the choroid plexus cell 
line. I was also involved in editing and proofing of the manuscript, as well as responding to 
reviewers’ comments, and tasked with conducting additional experiments requested of the 
reviewer. This included validation of the RT-PCR primers by sequencing the amplicons to 
demonstrate that the correct mRNAs had been amplified.  
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5.3 Abstract 
The choroid plexus (CP), composed of capillaries surrounded by a barrier epithelium, is the main 
producer of cerebrospinal fluid (CSF). The CP epithelium regulates the transport of ions and water 
between the blood and the ventricles, contributing to CSF production and composition. Several 
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studies suggest a connection between the cation channel Transient Receptor Potential Vanilloid-4 
(TRPV4) and transepithelial ion movement. TRPV4 is a non-selective, calcium permeable cation 
channel present in CP epithelia reported to be activated by cytokines and inflammatory mediators. 
Utilizing the PCP-R (porcine choroid plexus- Riems) cell line, we investigated the effects of 
various cytokines and inflammatory mediators on TRPV4-mediated activity. Select pro-
inflammatory cytokines (TNF-α, IL-1β, TGF-β1) had inhibitory effects on TRPV4-stimulated 
transepithelial ion flux and permeability changes whereas anti-inflammatory cytokines (IL-10, IL-
4, IL-6) had none. Quantitative mRNA analysis showed that these cytokines had no effect on 
TRPV4 transcription levels. Inhibition of the transcription factor NF-κB, involved in the 
production and regulation of several inflammatory cytokines, inhibited TRPV4-mediated activity, 
suggesting a link between TRPV4 and cytokine production. Contrary to published studies, the pro-
inflammatory mediator arachidonic acid (AA) had inhibitory rather than stimulatory effects on 
TRPV4-mediated responses. However, inhibition of AA metabolism also caused inhibitory effects 
on TRPV4, suggesting a complex interaction of AA and its metabolites in the regulation of TRPV4 
activity. Together these data imply that TRPV4 activity is involved in the inflammatory response; 
it is negatively affected by pro-inflammatory mediators. Furthermore, arachidonic acid metabolites, 
but not arachidonic acid itself, are positive regulators of TRPV4. 
5.4 Introduction 
Neurological and neurodegenerative conditions in the brain can result in an increase in the release 
of inflammatory mediators into the injured areas. These conditions can include head trauma, 
intracranial hemorrhage, infection, brain tumor, genetic defect or neurodegenerative disease (11, 
13, 16, 18, 20, 21, 27, 29, 45, 46). In many of these cases, the development of transient or chronic 
enlargement of the brain ventricles and an increase in pressure due to the accumulation of 
cerebrospinal fluid (CSF) occurs. This accrual of fluid could be caused by increases in 
inflammation affecting the production and/or absorption of the CSF. 
 
The main production of CSF comes from the choroid plexus (CP), present in the lateral, third, and 
fourth ventricles (10). Composed of a barrier epithelium that surrounds a network of capillaries, 
the CP epithelial cells regulate the transport of ions and water between the ventricles and capillaries 
via electrolyte transporters, thus controlling the production and composition of CSF. Aberrant 
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regulation of these transporters could be a causative agent leading to the emergence of 
fluid/electrolyte imbalances in the brain.  
 
Previous data suggest a link between transepithelial ion movement and the cation channel, 
Transient Receptor Potential Vanilloid-4 (TRPV4) (29, 37, 44). This ion channel is found in 
choroid plexus epithelium (10, 37). TRPV4 is a mechano-, osmo-, and temperature-sensitive, non-
selective, calcium-permeable cation channel that can serve as a hub protein for the activation of 
other transporters (26, 32, 37, 42). For example, in the porcine choroid plexus cell line – Riems 
(PCP-R), TRPV4 activation can lead to an influx of calcium into the cells, which subsequently 
stimulates calcium activated ion channels, such as the intermediate conductance potassium 
channels (37). Once these channels are activated, there is the potential for significant ion flux 
across the epithelia, resulting in compensatory water movement and a change in CSF production. 
TRPV4 can also be modulated through a number of stimuli, including chemical activators, such 
as cytokines and inflammatory mediators (26, 32, 37, 42). Indeed, it has been established that the 
inflammatory lipid endocannabinoid anandamide (AEA) and its metabolites, including 
arachidonic acid (AA), are capable of activating the channel (32). In addition, cytochrome P450 
epoxygenases, cyclooxygenases, and lipoxygenases can metabolize AA into both inflammatory 
and anti-inflammatory factors epoxyeicosatrienoic acids (EETs), prostaglandins, and 
hydroperoxides, respectively, which are also believed to stimulate TRPV4 activity (32, 33). 
 
Microglia, the macrophage-like cells of the central nervous system (CNS), can be triggered to 
release pro-inflammatory cytokines in response to abnormal protein accumulation or neuronal 
injury from chemical or physical means (7, 50). It is possible that such inflammation is associated 
with increases in CSF production associated with neurological disease (4, 17, 18, 35, 46). 
Summarized in Table 1, pro-inflammatory cytokines found upregulated in neurodegenerative 
states include interleukin (IL)-1β and tumor necrosis factor (TNF)-α. IL-10 and IL-4 are well-
documented anti-inflammatory cytokines also found in various neurological diseases. TGF-β and 
IL-6 have both been implicated in pro- as well as anti-inflammatory effects (2, 7, 8, 14, 15, 24, 38, 
41, 48). These cytokines can, therefore, potentially play a role in altering TRPV4 activity. 
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As an in vitro model, the PCP-R cell line can be utilized as a surrogate for in vivo CP tissue. This 
cell line exhibits many of the characteristics of the native epithelium including the formation of a 
barrier epithelial monolayer, expression of tight junctional proteins claudins 1 and 3, zona 
occludins-1 and occludin as well as the polarization of transporters and channels similar to those 
found in vivo (37, 39). A previous study has used this line to monitor changes in transepithelial ion 
flux and barrier permeability in response to factors that modulate choroid plexus electrolyte 
transporters in vivo (37). The polarity and barrier function exhibited by this cell line allows for 
experimentation modeling changes in the barrier function of choroid plexus in vivo (37, 39). Using 
a TRPV4 agonist, GSK1016790A, we are able to stimulate TRPV4 activation and observe changes 
in ion flux and transepithelial conductance in the presence of various cytokines and inflammatory 
mediators.  
 
In this paper, we show that specific cytokines and inflammatory mediators can alter the function 
of TRPV4 in PCP-R cell epithelia. This provides more insight into the role of the cation channel 
in neuro-inflammatory states and suggesting this hub protein as a potential effector in CSF 
production. 
5.5 Materials and Methods 
Cell Culture: PCP-R cells were grown on 0.4 µm pore diameter filters inserts (MilliporeSigma, 
Burlington, MA; #PIHP03050) until the cultures developed a high transepithelial electrical 
resistance (TER) (10-12 days) (37). Only cultures with resistances above 500 Ωcm2 were utilized. 
During experimental protocols that result in a change in resistance, cells that drop below 100 Ωcm2 
were also removed from analysis as their junctional complexes appear irreversibly altered. Cells 
were fed three times weekly with DMEM media (Gibco, Gaithersburg, MD; #12100-046) 
containing 4.5 g/L glucose, 3.7 g/L NaHCO3, 5.71 g/L HEPES, 10% fetal bovine serum (Atlanta 
Biologicals, Flowery Branch, GA), 100 U/mL penicillin, 100 mg/mL streptomycin, and 5 µg/ml 
insulin. Each plate contained 6 filters in 6 different wells. Filtered inserts were bathed in 2 mL 
feeding media on the basolateral (bottom) side of the membrane and 1.5 mL feeding media on the 
apical (top) side of the membrane.  
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Reverse Transcriptase (RT)-PCR: For the RT-PCR, cells were grown in 75 cm2 flasks until 
confluent. The monolayers were trypsinized, collected, and RNA from the cells extracted 
following the manufacturer’s instructions for the New Monarch Total RNA Miniprep Kit (New 
England BioLabs Inc., Ipswich, MA; #T2010S). No template controls and cDNA were prepared 
by following manufacturer’s protocol for the New England BioLabs LunaScript RT SuperMix Kit 
(#E3010S). Three primer sets for each gene were generated using Primer3Plus with mRNA 
sequences and tested on a temperature gradient. Only those primers used in the final images were 
included in Table 4.1. Sus scrofa mRNA sequences were obtained from Ensembl and additionally 
confirmed with sequences from the NCBI database. Forward and reverse primers (IDT) were 
combined with cDNA (approximately 500 ng) and GoTaq Green Master Mix (Promega 
Corporation, Madison, WI; #M7122) to perform gradients of PCR to determine the optimal 
annealing temperature. PCR products were then run on 1.5% agarose gels with ethidium bromide 
and 100bp flanking ladders. Gels were imaged using a ChemiDoc XRS imager (Bio-Rad, Hercules, 
CA). Following confirmation of single band amplification, PCR products were Sanger sequenced 
by Eton Bioscience (Union, NJ). Amplicons were confirmed to be the predicted transcript for each 
gene, validated using NCBI BLAST. 
 
Quantitative (q) PCR: Choroid plexus cells were grown on 0.4 µM polycarbonate filtered inserts 
(MilliporeSigma) until confluent (10-12 days). 24 hours prior to use, experimental cells were 
treated with specific cytokines and allowed to incubate overnight. Cells were washed with cold 
1X PBS twice, and total RNA was isolated using the Monarch Total RNA Miniprep Kit (New 
England Biolabs) according to the manufacturer’s instructions for cultured cells. Purified RNA 
concentration was measured using an ND2000 NanoDrop (Fisher Scientific, Waltham, MA). 
Approximately 100 ng of total RNA was reverse transcribed into cDNA using the Monarch 
LunaScript RT SuperMix Kit (New England Biolabs). cDNA was diluted 1:10 with Nuclease-Free 
water (New England Biolabs). qPCR was carried out on a LightCycler 480 Instrument II real-time 
PCR system (Roche LifeScience, Penzberg, Germany), using LightCycler 480 SYBR Green I 
Master Mix (Roche LifeScience, #04707516001). qPCR cycle conditions were 95°C for 5 minutes; 
followed by 45 cycles of 95°C for 10 seconds, 60°C for 10 seconds, and 72°C for 10 seconds. Data 
are presented as relative expression fold change using the 2-Δ ΔCT method (28) relative to the 
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calibrator housekeeping genes GAPDH and Rps18. Data are shown as fold change of TRPV4 in 
treated cells relative to the normalized controls. 
 
Electrophysiology: Electrophysiological measurements were conducted by excising and mounting 
confluent (10-12 days) PCP-R cells grown on filter inserts in Ussing chambers which are attached 
to a DVC-1000 Voltage/Current Clamp (World Precision Instruments, Sarasota, FL) using voltage 
and current electrodes. To each side of the chamber, 10 mL of 37˚C serum-free media was added. 
The chambers were water jacketed to allow the cells and media to be kept at a consistent 
physiological temperature (37˚C). Furthermore, the media was continuously oxygenated and 
circulated by bubbling 5% CO2/95% O2 directly into the media. Following clamping of the 
spontaneous transepithelial potential difference to zero for an equilibration period of at least 30 
minutes, experimental compounds were added to the apical and/or basolateral membranes by 
means of the serum-free media and the cultures were monitored for changes in short circuit current 
(SCC) and transepithelial resistance (TER). SCC is a measure of net transepithelial ion flux; a 
positive deflection indicates either anion absorption or cation secretion and a negative deflection 
indicates the reverse. TER is a measure of changes in epithelial barrier function and was measured 
every 200 seconds through a 2mV pulse. The instantaneous change in SCC from the pulse was 
used to calculate TERs by means of Ohm’s Law. These resistance calculations were converted to 
conductance by taking the inverse of the resistances. Conductance is a measure of transepithelial 
permeability. These parameters provided real time information about transepithelial ion flux in 
response to modulators of ion channels or intracellular signaling molecules. In each experiment, 
the cells were pre-incubated on both basolateral and apical sides with the experimental compounds 
for either 10 or 20 minutes or 24 hours prior to addition of TRPV4 agonist GSK1016790A as 
indicated on the figures. In all experiments, control and effector-treated samples were grown and 
analyzed in parallel cultures. 
 
Statistics: Statistics were performed using Two-tailed Students t-test in Sigma Plot 13. p < 0.05 is 
considered significant. Students t-test was used to compare experimental groups to the control 
group as well as the experimental groups to each other as indicated by the symbols defined in the 
figure legends. 
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5.6 Results 
The PCP-R cell line develops a high resistance monolayer when grown on permeable supports 
with optimal resistances occurring 9-12 days post seeding (Figure 3.1). Addition of the TRPV4 
agonist GSK1016790A to PCP-R cells causes an increase in transepithelial conductance indicating 
an increased permeability across the epithelial monolayer (Figure 3.2, top).  Concurrently with the 
initiation of the conductance change is a stimulation of short circuit current (SCC) indicating net 
electrogenic transepithelial ion flux composed of anion absorption (CSF to blood) and/or cation 
secretion (blood to CSF) (Figure 3.2, bottom).  Although the conductance remains elevated, the 
net electrolyte flux returns to a level that is statistically equal to the basal level within 20-30 
minutes after agonist addition.  A 10 minute pre-treatment with either of two structurally unrelated 
TRPV4 antagonists, HC067047 or RN1734, completely blocked the increased permeability of the 
monolayer as well as the electrogenic ion flux (Figure 3.2). To determine the maximal 
concentration of the agonist which did not result in an irreversible change in conductance and ion 
flux, a dose response was performed using concentrations of 0.1, 1, 3, 5, and 10 nM GSK1016790A 
(Figure 3.3). When the TER of the epithelial monolayer falls below 100 Ω*cm2 or the conductance 
rises higher than 10 mS/cm2 it is observed that the TER will continue to fall to unmeasureable 
levels and the experiment using this culture has to be discarded (data not shown). 
 
A limited dose response was also performed for the TRPV4 antagonist RN1734 at concentrations 
of 5, 25, and 50 µM in order to determine the maximal inhibitory concentration (Figure 3.4). 
Interestingly, the agonist-induced conductance responses are immediately reversible upon the 
addition of a TRPV4 antagonist.  This reversal is accompanied by a statistically significant change 
in the electrogenic flux (Figure 3.5). 
 
To visualize how the TRPV4 agonist was affecting the junctional complexes, PCP-R cells grown 
on Transwell filter supports were treated with GSK1016790A or diluent for 10 minutes before 
fixation and staining with anti-claudin-1 antibody (Figure 3.6).  During the incubations, the Ca2+ 
concentration was maintained by the use of serum-free media because changes in extracellular 
Ca2+ have profound effects on tight junctions and epithelial conductance (13,19).  The untreated, 
agonist treated, and negative control (no primary antibody) cells were grown in the same 6-well 
Transwell plate and were treated, fixed, stained and imaged in parallel.   No obvious difference 
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was observed between the junctional complexes in any of the monolayers examined; rather all 
junctional complexes remained intact. 
 
Stimulation of TRPV4 causes an influx of Ca2+ which is postulated to secondarily stimulate Ca2+-
activated channels.  Therefore primers were designed to determine the presence of Ca2+-activated 
K+ channels in the PCP-R cell line.  When negative results were obtained, a second primer pair 
was designed to confirm the results (Table 3.1).  The only Ca2+-sensitive K+ channels found in the 
PCP-R cell line were the intermediate conductance (IK; KCa3.1) and the small conductance (SK) 
2 channels (Figure 3.7).    As expected, TRPV4 is endogenously expressed in the cell line (Figure 
3.7). 
 
The RT-PCR results were followed by electrophysiological experiments. As expected from the 
PCR results, iberiotoxin, an inhibitor of big conductance potassium channels (BK; KCa1.1) had no 
effect on the TRPV4-stimulated conductance change or transepithelial ion flux (Figure 3.8).  
Unexpectedly, apamin, a pan-SK channel blocker, was also without effect on TRPV4-mediated 
ion flux or conductance changes (Figure 3.9).  A similar lack of effect on either 
electrophysiological parameter was noted after pre-incubation with the more SK2-specific 
inhibitors tamapin, Lei-Dab, or scyllatoxin (data not shown). 
Pre-treatment with low dose (1 µM) TRAM 34, an inhibitor of two of the three isoforms of IK, 
also termed Kcnn4, had no effect on the subsequent response to TRPV4 agonist. However, 
increasing the TRAM 34 concentration to 50 µM resulted in an inhibition of both the increased 
conductance and short-circuit current (Figure 3.10).   If a moderately high dose of TRAM 34 (25 
µM) was added to the apical bathing media during the pre-incubation, the response to the TRPV4 
agonist was completely inhibited; conversely if the same concentration was added only to the 
media bathing the serosal face of the tissue, there was a reduced inhibition of the ion flux 
accompanied by a substantial, but not complete, inhibition of the increased conductance (Figure 
3.11). 
5.7 Discussion 
TLRs are found on microglia, astrocytes, and other immune cells and are well known for playing 
a key role in the initiation of innate immunity in response to PAMPs and DAMPs. The TLRs not 
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only play a major role in a cell’s ability to respond to inflammatory reactions, but they also enable 
the cells to contribute to the inflammation. When the TLRs detect PAMPs or DAMPs, this can 
cause a cascade of events leading to activation of transcription factors NF-κB and AP-1 and 
subsequent cytokine production (6, 34). In particular, TLR4 is best known for producing key pro- 
and anti-inflammatory cytokines, such as TNF-α, IL-6, and IL-10, and is most often associated 
with inflammation (6, 34). It is also of interest that expression levels of TLRs have been found to 
change during aging (34). Specifically, pro-inflammatory cytokine production increases while 
secretion of anti-inflammatory cytokines decreases. TLRs have been associated with age-related 
inflammatory neurodegenerative diseases, such as ischemic stroke, Alzheimer’s disease, and 
multiple sclerosis (34).  
 
The PCP-R cell line contains mRNA for the receptors of most cytokines tested, except for IL-10, 
and all 10 of the known porcine TLRs. This indicates that CP cells have the potential to respond 
to cytokines and inflammatory signals as well as produce several different cytokines, which would 
be secreted into the CSF.  While we did not explore cytokine production in these studies, it is likely 
that autocrine or paracrine cytokines will have effects on CSF production by the CP cells. 
 
In studies using lung and endothelial tissue, TRPV4 antagonists have been found to reduce 
pulmonary edema and protect against sepsis, respectively. In both studies, TRPV4 inhibition was 
also found to decrease inflammation and cytokine production (3, 9). This would suggest that 
TRPV4 acts in a pro-inflammatory manner. To confirm this in the brain, we looked at various 
types of cytokines, including pro-inflammatory, anti-inflammatory, and paradoxical pro- and anti-
inflammatory cytokines. Indeed, long-term (24 hours) incubation with the pro-inflammatory 
cytokines had significant effects on TRPV4 activity. However, the responses seen with the two 
prominent pro-inflammatory cytokines were not the same. Furthermore, the paradoxical cytokines, 
TGF-β1 and IL-6, had varying effects with TGF-β1 causing strikingly similar results as IL-1β 
while IL-6 had no significant effect.  
 
The exact nature of the electrophysiological response to TRPV4 agonists is undoubtedly complex.  
We have previously shown that a component of the response is due to potassium secretion via the 
intermediate conductance (IK) channel (37).  However, the complex nature of the SCC response, 
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as well as the differential effects of cytokines on this response, strongly suggests a multitude of 
intersecting ion fluxes. SCC is a measure of net transepithelial ion movements.  Although the 
current returns to “baseline” about 30 minutes after treatment with a TRPV4 agonist, the sustained 
high conductance suggests a continued transepithelial ion flux with anions and cations moving in 
opposite directions, resulting in an electroneutral short circuit current, or net zero electrogenic flux.  
The cytokines that have an effect on net ion fluxes appear to be doing so by altering different 
components of the complex response. 
 
While it cannot be assumed that all pro-inflammatory pathways cause an attenuation or inhibition 
of the response, it is most likely, based upon our observations, that TGF-β1 is acting in a pro-
inflammatory manner while IL-6 is acting in an anti-inflammatory manner in the CP cells. 
Together, these data imply that pro-inflammatory cytokines diminish TRPV4 function. While 
upstream activators, TNF-α and IL-1β, required 24 hours to mediate a measurable effect on the 
PCP-R cells, the finding that short-term inhibition of the pro-inflammatory transcription factor 
NF-κB caused a potentiation of TRPV4-mediated ion flux and permeability changes cannot be 
easily explained. This may indicate a preexisting tone of NF-κB activation in the PCP-R cells. The 
inhibition of this baseline activity may cause an increase in barrier permeability as ions are more 
easily able to move across the membrane. After 24 hours of inhibition, the basal conductance is 
substantially higher than the control, which further suggests underlying NF-κB activity. However, 
the attenuated response upon TRPV4 stimulation suggests that NF-κB activation, and possibly its 
downstream inflammatory effectors, can be considered contributors to TRPV4-mediated ion flux 
and permeability changes.  
 
Effects seen after long-term cytokine incubations raised the question of whether the changes in 
TRPV4-mediated activity were due to an alteration of the transcription of TRPV4. However there 
were no statistical differences in the quantitative PCR of TRPV4 in response to 24-hour cytokine 
incubations indicating that the cytokines are having an effect on the downstream targets of the ion 
channel.  
 
Several publications have reported that AA and its metabolites are able to cause a substantial 
elevation of [Ca2+]i by activating TRPV4 with concentrations as low as 3 µM AA (5, 31, 47). 
 
 
158 
Specifically, these studies also cite EETs as the predominant activator of the cation channel (5, 7, 
32, 47). However, it has also been reported that endogenous levels of AA can differ depending on 
the tissue type, with physiological concentrations varying from 2 to 16 µM. In pancreatic islet cells, 
the concentration was found to be as high as 75 µM (31). Based on previous studies, we 
hypothesized that TRPV4 activity would be potentiated after pre-incubation with either 
physiological concentrations of AA or its metabolites. Surprisingly, concentrations of AA 
comparable to previous publications (10 µM) failed to potentiate TRPV4-mediated activity. Rather, 
AA (up to 100 µM) caused an inhibition of the TRPV4-mediated response to transepithelial ion 
flux and cell permeability in a dose-dependent manner. AA inhibition of TRPV4-mediated ion 
flux in the PCP-R cells suggests a cell-type specific effect on TRPV4.  Taken together with our 
cytokine data, in which selective pro-inflammatory cytokines down regulate TRPV4-mediated 
activity, this would imply that inflammation acts to decrease TRPV4 function. 
 
There is controversy concerning which isoform of EET is responsible for activating TRPV4 (12). 
It is possible that different isoforms of EET affect TRPV4 in a cell-specific manner. While 5,6-
EET is most often considered to be the activating isoform in other cell types, this does not appear 
to be the case when added exogenously in CP cells. It is possible that the 5,6-EET is only effective 
when produced inside the cells. However, it is unknown whether the PCP-R cell line is able to 
produce EETs. The production of EETs occurs when AA is metabolized by the enzymes 
cytochrome P450 epoxygenase, of which there are multiple isoforms (40). Currently, only two of 
these enzymes have been sequenced in pigs, Cyp2c42 and Cyp2e1, neither of which were present 
in the cells. However, there are several other isoforms still untested, including those most 
associated with EET production, Cyp2c8, Cyp2c9, Cyp2c19 and Cyp2j2 (40). Therefore, these data 
cannot lead to the conclusion that there are no cytochrome P450 epoxygenases present. 
Furthermore, the dramatic inhibitory effects of the SKF-525A CYP450 inhibitor imply that 
endogenous EET production may activate TRPV4 in these cells. It is possible that a different EET 
isoform other than 5,6-EET is affecting TRPV4 in the CP or that the production occurs within a 
membrane limited compartment that is closely linked to the channel. 
 
We determined the potential effects of the other AA metabolites in the CP cells. Both isoforms of 
cyclooxygenase were present in the PCP-R cells, therefore the cells are able to produce 
 
 
159 
prostaglandins, prostacyclin, and thromboxane A2 (36). However, inhibition of both COX1 and 
COX2 with the NSAID Indomethacin did not alter the effects of TRPV4 activation in the cells. 
Thus, these metabolites likely do not play a role in TRPV4-mediated pathways. 
 
The lipoxygenase (LOX) pathway contains seven known gene isomers: Aloxe3, -5, -5ap, -12, -12b, 
-15, and -15b (30). Of the enzymes, ALOX12B, -E3, and -15B are found in the skin and other 
epithelial cells and ALOX5, -12, and -15 are located primarily in immune cells. Many of the 
isomers have been reported in different forms of cancers, but all of them can be involved in 
inflammation (30). Of the four sequenced porcine isomers, only ALOX15 and ALOX15B were 
found in our cell line. Interestingly, ALOX15 is considered one of the isoforms that can be partially 
controlled by cytokines. Anti-inflammatory cytokines, such as IL-4 and IL-13, have the potential 
to increase expression of this gene, which can then decrease production of pro-inflammatory 
cytokines, such as IL-12 (30). The isoform has also been associated with maintaining dermal 
integrity through anti-inflammatory suppression of inflammation in the skin (19). On the other 
hand, ALOX15 is also capable of increasing pro-inflammatory matrix metalloproteinase (MMP) 
expression and contributing to arthritic disease progression (49, 53). Once again, this leads to the 
question of whether TRPV4 is part of a pro- or anti-inflammatory process. Less is known about 
the ALOX15B isoform, but it has been implicated in decreasing epithelial barrier permeability 
(30). Thus, increases in this isoform could contribute to increases in transepithelial ion flux and 
conductance in the CP tissue. 
 
As previously stated, inhibiting cyclooxygenases alone does not affect the cellular response to 
TRPV4 agonists. However, when both cyclooxygenases and lipoxygenases are inhibited, there is 
a partial inhibition of the TRPV4-mediated response. As shown above, inhibiting the CYP450s 
and subsequent EET production results in complete inhibition of the TRPV4-mediated response. 
Thus, the interaction between the AA metabolites and TRPV4 is complicated and may involve 
both positive and negative effectors produced in a stimulus dependent manner. Future experiments 
will investigate how these metabolites interact with the channel. 
 
In summary, TRPV4-mediated transepithelial ion flux and increases in conductance are negatively 
affected by pro-inflammatory cytokines and mediators. We also found that, in contrast to 
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previously reported studies, arachidonic acid does not increase TRPV4-related activity. Rather, 
when added to choroid plexus cells, arachidonic acid diminished TRPV4-mediated transepithelial 
ion flux and changes in permeability. Finally, we confirmed that in the choroid plexus, inhibition 
of EET production causes a complete inhibition of TRPV4-mediated transepithelial ion flux and 
cellular permeability changes. Therefore, in the choroid plexus, TRPV4 regulation by 
inflammatory mediators is complex, consistent with the role of this channel as a hub protein which 
can integrate multiple extracellular signals and subsequently mediate a multiphasic change in 
transepithelial ion transport. 
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Table 5.1 Reported Cytokine Functions in the Inflammatory Pathway. 
Inflammation Pathway Cytokines References 
Pro-inflammatory IL-1β, TNF-α 2, 7, 15, 41, 48 
Anti-inflammatory IL-10, IL-4 15, 41, 48 
Pro- and Anti-Inflammatory TGF-β, IL-6 2, 7, 8, 14, 15, 24, 38, 41, 48 
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Table 5.2 Sus Scrofa Primers Used for RT-PCR with Corresponding Product Sizes (bp).  
Three different primer sets were generated and tested for each gene. Primers included in this table 
were utilized for Figures 1A, B, and C. GAPDH was used as a positive control. 
Sus 
Scrofa 
gene 
Protein Primer Sequences 5' - 3' Product 
Size (bp) Forward Primer Reverse Primer 
Il1r1 IL1R1 TTACACAGAGACTACCGGTTGC CAGTTTTATCACCCGGGAGACA 263 
Il1r2 IL1R2 AAATGATTCCACGACCATCCCA TCCCAAAACCAGGATGATGAGG 874 
Tnfrsf1a TNFRSF1A GAAACAGGACACCATCTGCAAC AAGCTAAGCCAACGAAGAGGAA 218 
Tgfbr1 TGFBR1 GAGACAGGCCATTTGTATGTGC TAAATCTCTGCCTCACGGAACC 520 
Tgfbr2 TGFBR2 GGAAGCTGATGGAGTTCAGTGA TCTCTGTCTTCCAGGAGGCATA 252 
Tgfbr3 TGFBR3 ATATTCACCACAAGCCTGTCGT ATACTCCTTTCGGGCCCAATTT 224 
Il6r IL6R AAGATTCTGCGTCGGTACCATT TGTTGCTGACATCATAAGGGCT 312 
Il10ra IL10RA GGATGAAGTGACTCTGACGGTT GCTTCACCCTGACACACAATTC 257 
Il4r IL4R AGAGCTACCTGTACTCGGAACT CCCTTTGTCTTCCTCCTCTTCC 695 
Tlr1 TLR1 TGTCCCACAACAAGTTGGAGAA TTGTGGGAAACTGAACACCTCA 650 
Tlr2 TLR2 TCCCAAATCTGCGAATCCTGAA ATGCAACCTCCGGACTGTTAAT 512 
Tlr3 TLR3 CGATGACCTCCCGGCAAATATA GAGATTTTCCAGTTGGAGCTGC 382 
Tlr4 TLR4 TTCTCTCCTGCCTGAGATCTGA ACTCCAGGTAGGTATTCCTGCT 555 
Tlr5 TLR5 TCCTGTGGTCTCTCTGATGCTA GGGTTCATACACTTCCCCCAAT 284 
Tlr6 TLR6 AGACAATCTTGTGCCATCCCAT GGCCCTTGAGTGAGTTCCAATA 409 
Tlr7 TLR7 GACACTAAAGACCCAGCAGTGA CTGAAGGGGCTTCTCAAGGAAT 297 
Tlr8 TLR8 CTGAGGCAGAACAGGATTTCCT TTCATCACCCAGTCTGTGACAG 542 
Tlr9 TLR9 GCCTACGAACTCTCAACCTCAA GGAAGTTCTCACTCAGGTCCAG 696 
Tlr10 TLR10 TCAGGTGCTTGCCCAGAAATAT TCTTGCCAGGATCAGAGTTTCC 717 
Cyp2c42 CYP2C42 TCCTGTCTGCTTCTCCTTTCAC GGGAGCACAGTCCAGGATAAAA 489 
Cyp2e1 CYP2E1 TCGAGATTTCACTGACACCCTG GTTAAAGTGCTGCAAGATGGCA 592 
Alox5 5-LOX TGACAGTGGATGAAGAACTGGG TGTTTTTGCCGTGTTTCCAGTT 259 
Alox12b 12R-LOX ACACCATCCAGATCAACAGCAT CCAGAGGACCAATAGGACGATG 602 
Alox15 12/15-LOX CAGGAGGATGAACTCTTTGGCT TCGAATATACCTCCGTCCGAGA 578 
Alox15b 15-LOX2 GCGAAATGCTGAGTTCTCCATC CAGGGTGGAATAGTTCAGCTGT 283 
Cox1 COX1 TCACCCGCAATACTATGAGCTC TGTGTGATAGGGAGGAGGACAT 510 
Cox2 COX2 CCCTTTCCAACTAGGCTTCCAA TAGTCGTCCTGGGATAGCATCT 529 
Gapdh GAPDH TTTTAACTCTGGCAAAGTGGAC CATTGTCGTACCAGGAAATGAG 884 
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Figure 5.1: RT-PCR in PCP-R cells. A) mRNA for the various cytokine receptors. All were 
present except for the second isoform of the IL-1 receptors (Il1r2) and the IL-10 receptor 
(Il10ra). B) mRNA for porcine Toll-like receptors (TLR) 1-10 is present in the PCP-R cell 
line. C) RT-PCR results for various enzymes capable of arachidonic acid (AA) metabolism. 
Cytochrome P(CYP)450 epoxygenases, Cyp2c42 and Cyp2e1, are both absent. mRNA for 
lipoxygenase (Alox)15 and Alox15b are present whereas Alox5 and Alox12 are absent. 
Cyclooxygenase (Cox) 1 and 2 are both present. Gapdh was utilized as positive controls for 
each gel. Band product sizes can be found in Table 2. Ladder = 100 bp. T = Template. Lanes 
denoted (+) or (-) “T” signifies addition or no addition of template control. D) Diagram of AA 
metabolism via the three different pathways, pathway inhibitors, and subsequent metabolites. 
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Figure 5.1 RT-PCR in PCP-R Cells. 
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Figure 5.2: Pre-treatment of PCP-R cells with pro-inflammatory cytokine IL-1β for 24-hours 
prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was 
measured. IL-1β (10 ng/mL in PBS) was added to the PCP-R media on both basolateral and 
apical sides of the membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A 
was added to basolateral side of the membrane only at T = 0 minutes. 24-hour incubation with 
IL-1β is signified by white circles.  GSK1016790A control is signified by black circles. Circles 
signify mean values and bars signify ±S.E.M. for number of experiments indicated. SCC = 
short circuit current. * = p < 0.05 against control. 
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Figure 5.2 Treatment of PCP-R Cells with IL-1β 24-hrs Prior to TRPV4 Agonist Addition. 
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Figure 5.3: Pre-treatment of PCP-R cells with pro-inflammatory cytokine TNF-α for 24-hours 
prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was 
measured. TNF-α (0.15 ng/mL in deionized water) was added to the PCP-R media on both 
basolateral and apical sides of the membrane at T = -24 hours (not shown). TRPV4 agonist 
GSK1016790A was added to basolateral side of the membrane only at T = 0 minutes. 24-hour 
incubation with TNF-α is signified by white circles.  GSK1016790A control is signified by 
black circles. Circles signify mean values and bars signify ±S.E.M. for number of experiments 
indicated. SCC = short circuit current. * = p < 0.05 against control.  
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Figure 5.3 Treatment of PCP-R Cells with TNF-α 24-hrs Prior to TRPV4 Agonist Addition. 
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Figure 5.4: Pre-treatment of PCP-R cells with pro- and anti-inflammatory cytokine TGF-β1 for 
24-hours prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance 
was measured. TGF-β1 (2 ng/mL in 4 mM HCl) was added to the PCP-R media on both 
basolateral and apical sides of the membrane at T = -24 hours (not shown). TRPV4 agonist 
GSK1016790A was added to basolateral side of the membrane only at T = 0 minutes. 24-hour 
incubation with TGF-β1 is signified by white circles.  GSK1016790A control is signified by 
black circles. Circles signify mean values and bars signify ±S.E.M. for number of experiments 
indicated. SCC = short circuit current. * = p < 0.05 against control.  
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Figure 5.4 Treatment of PCP-R Cells with TGF-β1 24-hrs Prior to TRPV4 Agonist Addition. 
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Figure 5.5: Pre-treatment of PCP-R cells with anti-inflammatory cytokine IL-6 for 24-hours 
prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was 
measured. IL-6 (10 ng/mL in 4 mM HCl) was added to the PCP-R media on both basolateral 
and apical sides of the membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A 
was added to basolateral side of the membrane only at T = 0 minutes. 24-hour incubation with 
IL-6 is signified by white circles.  GSK1016790A control is signified by black circles. Circles 
signify mean values and bars signify ±S.E.M. for number of experiments indicated. SCC = 
short circuit current. 
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Figure 5.5 Treatment of PCP-R Cells with IL-6 24-hrs Prior to TRPV4 Agonist Addition. 
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Figure 5.6: Pre-treatment of PCP-R cells with anti-inflammatory cytokine IL-10 for 24-hours 
prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was 
measured. IL-10 (5 ng/mL in PBS) was added to the PCP-R media on both basolateral and 
apical sides of the membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A 
was added to basolateral side of the membrane only at T = 0 minutes. 24-hour incubation with 
IL-10 is signified by white circles.  GSK1016790A control is signified by black circles. Circles 
signify mean values and bars signify ±S.E.M. for number of experiments indicated. SCC = 
short circuit current. 
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Figure 5.6 Treatment of PCP-R Cells with IL-10 24-hrs Prior to TRPV4 Agonist Addition. 
 
 
175 
  
  
Figure 5.7: Pre-treatment of PCP-R cells with pro- and anti-inflammatory cytokine IL-4 for 
24-hours prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance 
was measured. IL-4 (20 ng/mL in PBS) was added to the PCP-R media on both basolateral and 
apical sides of the membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A 
was added to basolateral side of the membrane only at T = 0 minutes. 24-hour incubation with 
IL-4 is signified by white circles.  GSK1016790A control is signified by black circles. Circles 
signify mean values and bars signify ±S.E.M. for number of experiments indicated. SCC = 
short circuit current. 
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Figure 5.7 Treatment of PCP-R Cells with IL-4 24-hrs Prior to TRPV4 Agonist Addition. 
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Figure 5.8: Pre-treatment of PCP-R cells with NF-κB inhibitor PDTC for 10 minutes prior to 
TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was measured. 
PDTC (10 µM in DMSO) was added to the PCP-R media on both basolateral and apical sides 
of the membrane at T = -10 minutes. TRPV4 agonist GSK1016790A was added to basolateral 
side of the membrane only at T = 0 minutes. 10-minute incubation with PDTC is signified by 
white circles.  GSK1016790A control is signified by black circles. Circles signify mean values 
and bars signify ±S.E.M. for number of experiments indicated. SCC = short circuit current. * 
= p < 0.05 against control. 
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Figure 5.8 Treatment of PCP-R Cells with PDTC 10-min Prior to TRPV4 Agonist Addition. 
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Figure 5.9: Pre-treatment of PCP-R cells with NF-κB inhibitor PDTC for 24-hours prior to 
TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was measured. 
PDTC (10 µM in DMSO) was added to the PCP-R media on both basolateral and apical sides 
of the membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A was added to 
basolateral side of the membrane only at T = 0 minutes. 24-hour incubation with PDTC is 
signified by white circles.  GSK1016790A control is signified by black circles. Circles signify 
mean values and bars signify ±S.E.M. for number of experiments indicated. SCC = short circuit 
current. * = p < 0.05 against control. 
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Figure 5.9 Treatment of PCP-R Cells with PDTC 24-hrs Prior to TRPV4 Agonist Addition.  
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Figure 5.10 Relative Fold Change in TRPV4 24-hrs Post Incubation with Specific Cytokines. 
Relative fold change of TRPV4 mRNA in PCP-R cells 24 hours post-incubation with specific 
cytokines known to be involved in inflammatory responses. TNF-α (0.15 ng/ml), IL-1β (10 ng/ml), 
TGF-β1 (2 ng/ml), IL-4 (10 ng/ml), IL-6 (20 ng/ml), or IL-10 (5 ng/ml) were added both apically 
and basolaterally in individual wells (n=5 for each cytokine). The fold change of TRPV4 in treated 
wells is presented relative to the normalized controls (n=6). GAPDH and RPS18 were used as 
housekeeping genes to determine the 2-ΔΔCT fold change in TRPV4. The minimum and maximum 
fold-change values are shown as individual points on the graph. Circles signify the maximum and 
minimum values. Lines within the boxes signify mean values and bars signify ±S.E.M.  for number 
of experiments indicated. 
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Figure 5.11: Effect of a range of concentrations of arachidonic acid (AA) on TRPV4-mediated 
transepithelial ion flux and cellular permeability. AA solubilized in 100% EtOH was added to 
the PCP-R media on both basolateral and apical sides of the membrane at T = -10 minutes. 
TRPV4 agonist GSK1016790A was added to basolateral side of the membrane only at T = 0 
minutes. AA pre-treatment at 10 µM is signified by white circles. AA pre-treatment at 100 µM 
is signified by gray circles. GSK1016790A control is signified by black circles. Circles signify 
mean values and bars signify ±S.E.M. for number of experiments indicated. SCC = short circuit 
current. * = p < 0.05 against control. τ = p < 0.05 against 10 µM AA pre-treatment. 
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Figure 5.11 Treatment of PCP-R Cells with AA 24-hrs Prior to TRPV4 Agonist Addition.  
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Figure 5.12 Dose Effect of AA on TRPV4-Mediated Transepithelial Ion Flux. 
Dose effect of arachidonic acid (AA) on the change in TRPV4-mediated transepithelial ion flux in 
response to TRPV4-agonist GSK1016790A. PCP-R cells were pre-treated with arachidonic acid 
(AA) solubilized in 100% EtOH at various concentrations 10 minutes prior to TRPV4 agonist 
addition. AA was added to the PCP-R media on both basolateral and apical sides of the membrane. 
The change in transepithelial ion flux was measured 5 minutes after TRPV4 agonist addition 
(∆SCC). Error bars signify the S.E.M. for number of experiments indicated. ΔSCC = change in 
short circuit current. * = significant against 0 µM AA control with p values given.  
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Figure 5.13: Pre-treatment of PCP-R cells with arachidonic acid (AA) metabolism inhibitors 
20-minutes prior to TRPV4 agonist addition. Effect of inhibitor pre-incubation on TRPV4-
stimulated transepithelial ion flux and conductance was measured. All inhibitors were 
solubilized in 100% EtOH. Cyclooxygenase and lipoxygenase inhibitor ETYA was added to 
the PCP-R media on both basolateral and apical sides of the membrane at T = -20 minutes. 
Cytochrome P450 inhibitor SKF-525A was added to the PCP-R media on both basolateral and 
apical sides of the membrane at T = -20 minutes. TRPV4 agonist GSK1016790A was added 
to basolateral side of the membrane only at T = 0 minutes. ETYA pre-treatment is signified by 
white circles.  SKF-525A pre-treatment is signified by grey circles. GSK1016790A control is 
signified by black circles. Circles signify mean values and bars signify ±S.E.M. for number of 
experiments indicated. SCC = short circuit current. * = p < 0.05 against control. τ = p < 0.05 
against ETYA pre-treatment. 
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Figure 5.13 AA Metabolite Treatment of PCP-R Cells Prior to TRPV4 Agonist Addition.   
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Figure 5.14: Pre-treatment of PCP-R cells with arachidonic acid metabolite 5,6-EET at 10-
minutes prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance 
was measured. 5,6-EET solubilized in 100% EtOH was added to the PCP-R media on both 
basolateral and apical sides of the membrane at T = -10 minutes. TRPV4 agonist 
GSK1016790A was added to basolateral side of the membrane only at T = 0 minutes. 10-
minute incubation is signified by white circles.  GSK1016790A control is signified by black 
circles. Circles signify mean values and bars signify ±S.E.M. for number of experiments 
indicated. SCC = short circuit current.  
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Figure 5.14 Treatment of PCP-R Cells with 5,6-EET Prior to TRPV4 Agonist Addition. 
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 SUMMARY 
6.1 Summary 
The mechanisms of CSF production are still not fully understood. Currently, a large body of 
research exists implicating various transporters, channels, and aquaporins in playing significant 
roles in the movement of ions and water, necessary for the production of CSF. Additionally, many 
kinases have been shown to play key roles in the regulation of these events. However, while 
various studies have highlighted several possible pathways by which CSF production can be 
reduced and modulated, no consensus has been reached regarding which proteins establish the net 
driving forces, and which act as key regulators. In the field of hydrocephalus, there is a large unmet 
need; that of an effective drug treatment to reduce the production of CSF as an alternative to 
invasive surgeries. To that end, these studies have contributed to better understanding the 
mechanisms by which CSF is produced, and regulatory pathways which may be further studied to 
ultimately modulate how much CSF is being produced in patients with hydrocephalus. 
 
Using the PCP-R cell in vitro model, we have established a method by which we can study the 
transepithelial movement of ions in CP cells. This allows us to investigate the molecular 
mechanisms by which CSF is being produced, as well as determine how signals are being 
integrated, and which proteins interact to regulate the movement of ions across the epithelium. 
Using the cell line, we have also been able to study the barrier nature of the cells, and determine 
which effectors play roles in maintaining or compromising the integrity of this barrier. Through 
use of these effectors, we gain insight in to the roles played by various proteins in barrier 
maintenance.  
 
The PCP-R cell line is comprised of a high-resistance monolayer epithelium and closely mimics 
the barrier characteristics observed in the native in vivo tissue. Many of the same junctional 
proteins, such as Zona Occludens 1 and Claudin-1 are present in both the in vivo tissue and the 
PCP-R cells. Additionally, similarly to the native tissue, the PCP-R cells polarize, expressing 
different proteins on each membrane. This polarization allows for net transepithelial ion flux from 
either the blood (basolateral) to CSF-facing (apical) surfaces, or from CSF to blood. This model 
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therefore allows us to use drugs targeted to specific proteins to interrogate the role of many of the 
polarized proteins in moving ions in to, and out of the cell. 
 
In this thesis we have functionally characterized many key transporters and ion channels in the 
PCP-R cell line which have been previously described in human and rodent choroid plexus. This 
includes the Ca2+-activated K+ channels described in chapter 2 (SK2 and IK), the Na+/K+/Cl- and 
potassium-chloride cotransporters described in chapter 3 (NKCC1, KCC1-4), and the chloride 
channels described in chapter 4 (TMEM16A, AE2, NCBE, CFTR). In addition, we have identified 
mRNA for additional proteins previously described in the choroid plexus including carbonic 
anhydrase II, Na+/K+-ATPase and aquaporin 1 which have been suggested to play key roles in 
CSF production and cell homeostasis (data not shown). 
 
We have begun to assemble a mechanism by which TRPV4 is capable of stimulating 
transepithelial ion flux, and ultimately, the production of CSF. First, in chapter 2 we demonstrated 
that the IK channel, a Ca2+-activated K+ channel, is necessary for activation of TRPV4. It appears 
that the influx of Ca2+ which occurs in response to TRPV4 activation is responsible for activation 
of the IK channel, leading to secretion of potassium. In addition to this, in chapter 4 we showed 
that TMEM16A, a Ca2+-activated Cl- channel plays a significant role in the TRPV4 mechanism. 
We demonstrated that TRPV4 and TMEM16A are co-dependent on each other for activation. 
Inhibition of either TMEM16A or TRPV4 resulted in inhibition of the other, blocking the resulting 
transepithelial currents. Additionally, we showed that [Cl-] is tightly regulated within the cells, and 
is the key ion for cell homeostasis. From this, in chapter 3 we explored a role for NKCC1 in the 
TRPV4 mechanism. It has been previously shown in the literature that in the choroid plexus, 
NKCC1 is responsible for regulation of [Cl-]. Here we showed that NKCC1 does in fact play some 
role in the TRPV4-stimulated pathway, being capable of inhibiting a portion of the TRPV4-
induced transepithelial ion flux. 
 
We also wanted to determine whether the regulation of this mechanism was controlled by channel 
activation via kinases, or whether the mechanism was controlled at the transcriptional level. In 
chapter 3, we investigated whether the WNK-SPAK/OSR1 pathway could be responsible for 
activation of TRPV4, and could therefore be used as a regulator of the pathway. Here we 
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demonstrated that inhibition of SPAK activation via WNK was indeed capable of inhibiting 
TRPV4, although it appeared to be independent of NKCC1. This demonstrates that SPAK may 
instead act directly on TRPV4. Finally, to address whether these channels or transporters were 
regulated at the transcriptional level, we inhibited NKCC1 and SPAK. With respect to NKCC1, 
inhibition did not appear to affect its own gene regulation or that of any other channel. When 
inhibiting SPAK, we observed that the expression of NKCC1, WNK3 and SPAK were all 
decreased approximately 2-fold, while no effect was seen on TRPV4 transcription. 
 
In conclusion, we have identified several ways in which TRPV4 may work to stimulate the 
production of CSF, as well as identified some potential regulatory pathways by which the CSF 
production can be reduced. These studies, in conjunction with the many other studies in the field 
of CSF production may ultimately lead to new insights and innovations which can be used to 
develop targeted drugs to ameliorate the pathophysiology associated with hydrocephalus.  
6.2 Addressing the PCP-R Cell Polarity 
Following the writing of this thesis, but prior to final drafting, a concerning discovery was made 
regarding the polarity of the PCP-R cells. As has been described throughout this thesis, NKCC1 
and Na+/K+-ATPase have both been identified in the apical membranes of native choroid plexus 
in several model systems. A recent experiment performed by a collaborator demonstrated that both 
are localized in the basolateral rather than apical membrane in the PCP-R cells. This suggests that 
the cells are not correctly polarized and raises concerns about the cells as a model of secretory CP 
epithelia. It also brings in to question data regarding the role of NKCC1 in TRPV4-mediated 
transport.  
Additional experiments are being conducted by other members of the lab to address these concerns, 
and future publications will further address the differences in polarity between the PCP-R cells 
and another choroid plexus cell model, the human choroid plexus papilloma derived (HIBCPP) 
cell line. These experiments will serve to address the PCP-R cell line as a model of the choroid 
plexus, and will attempt to further tease out the role of NKCC in the TRPV4 mechanism. 
Unfortunately, given these findings, the two papers I have prepared for publication, chapters 3 and 
4 cannot be submitted in their current form. I will be conducting additional experiments utilizing 
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a human choroid plexus (HIBCPP) cell line during the remaining time in the laboratory and will 
work with my co-authors to modify the papers for publication. 
